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Lucas Solano, Synthesis and Evaluation of Novel Small Molecules as Potential 
Anti-Cancer Agents for The Treatment of Solid Tumors, Doctor of Philosophy 
(Integrated Biosciences), University of Minnesota.  
The primary focus of this thesis is to design, synthesize, characterize and 
evaluate novel small molecules as potential anti-cancer agents for the treatment 
of solid tumors. In this regard, we carried out three projects and synthesized 
numerous molecules with distinct mechanisms of actions. In project one, we 
synthesized indazole appended diphenyl urea molecules as multi-tyrosine kinase 
targeted anti-cancer agents. The lead candidate compounds exhibited excellent 
cell proliferation inhibition against various solid tumor cell lines including, murine 
metastatic breast cancer 4T1, murine glioblastoma Gl261-Luc2, human triple 
negative breast cancer MDA-MB-231, human pancreatic MIAPaCa-2, and 
human colorectal adenocarcinoma WiDr.  The lead candidate compounds were 
found to be well tolerated in healthy mice and exhibited significant tumor growth 
reduction in WiDr xenograft and 4T1 syngraft flank models in mice. In the second 
project, we have introduced a novel cytotoxicity enhancing pharmacophore with 
SN2 /SN2’ isomerization with nucleophilic cellular components. As an application 
of this pharmacophore, we appended to piperazinyl curcuminoids and 
synthesized several highly soluble quaternary ammonium derivatives. All of the 
synthesized compounds were evaluated for their cell proliferation inhibition 
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against three cancer cell lines, MIAPaCa-2, WiDr, and MDA-MB-231. The lead 
candidate compound was tested in a MIAPaCa-2 xenograft in mice and it 
exhibited significant tumor growth inhibition.   
In project three, we designed and synthesized chalcone appended 
cyanocinnnamic acids as potential glycolysis and mitochondrial oxidative 
phosphorylation inhibitors for the treatment of cancers. Chalcone acts as an 
irreversible covalent linker and the doubly activated cyanoacrylic acid unit as a 
potential reversible inhibitor of monocarboxylate transports and mitochondrial 
pyruvate carriers. The synthesized compounds have been evaluated for cell 




TABLE OF CONTENTS 
Acknowledgements………………………………………………………………... i 
Abstract……………………………………………………………………………. ii 
Table of contents………………………………………………………………….. iii 
List of schemes……………………………………………………………………. vii 
List of tables……………………………………………………………………… x 
List of figures………………………………………………………………………. x 
List of abbreviations………………………………………………………………. xxiv 
Chapter 1: Design of Novel Angiogenesis Inhibitors as Potential Anticancer Agents 
1.1 Introduction 
1.1a Cancer Heterogeneity and Hallmarks 
1.1bTyrosine Kinases and their role in cancer 
1.1c Epidermal growth factor receptor (EGFR) family 
1.1d EGFR Inhibitors  
1.1e Fibroblast growth factor receptor (FGFR) family 
1.1f Vascular endothelial growth factor receptor (VEGFR) family  
1.2: Results and discussion 
1.2a Synthesis of carboxy indazole diphenyl ureas as anticancer agents 
1.2b Cell proliferation study of compounds 1.5a-1.5k using MTT assay 
1.2e Endothelial Cell Tube Formation Assay of compounds 1.5i and 1.8i 
1.2f Systemic toxicity evaluation of N,N-dialkyl/diaryl o-methoxy CHC 
derivatives 3h-3k in CD-1 mice: Results and discussion 
v 
 
1.2g In vivo anticancer efficacy studies using lead candidate compounds:  
Anticancer efficacy of compounds 1.5i, 1.7i, and 1.8i in colorectal adeno 
carcinoma WiDr flank model 
1.2h Anticancer efficacy of lead candidate compound 1.8i in syngeneic 
4T1-luc2 flank model: 
1.3 Conclusions 
1.4 Experimental 
1.4a Chemicals and methods of compound characterization 
1.4b Synthesis of compounds 1-1.8i 
1.4c Cell lines and culture conditions 
1.4d MTT assay 
1.4e Endothelial Cell Tube Formation Assay  
1.4f Ethical Considerations for animal studies 
1.4g General procedure for systemic toxicity evaluation 
1.4h Anticancer efficacy of compound 1.5i, 1.7i, and 1.8i in WiDr flank 
model 
1.4i Anticancer efficacy of compound 1.8i in 4T1 flank model: 
1.5 NMR Spectra 
 
Chapter 2: Synthesis and Evaluation of Piperazinyl Curcuminoids Salts 
2.1 Introduction  
2.1a Natural products as Medicinal Agents 
vi 
 
2.1b Turmeric and its anticancer agent Curcumin 
2.1c Chemical properties of Curcumin 
2.1d Curcumin as a therapeutic agent  
2.1e Curcumin formulations 
2.1f Baylis-Hillman reaction 
2.1g Quaternary ammonium salts 
2.1h Mitochondrial targeting agents with Quaternary salts 
2.2 Results and Discussion: 
2.2a Synthesis of piperazine substituted curcumin analogs 
2.2b Cell proliferation/cytotoxicity study of compounds 2d-2f:  
2.2c Design of novel water soluble curcuminoids as potential anticancer 
agents 
2.2d Cell proliferation/cytotoxicity study of compounds 2g-2m: 
2.2e Florescence microscopy study of compound 2i in MIAPaCa-2 cells 
2.2f Systemic toxicity evaluation of compound 2i in CD-1 mice 
2.2g Anticancer efficacy of compound 2i in pancreatic cancer MIAPaCa-
2 xenograft model in athymic nude mice 
2.3 Conclusions 
2.4 Experimental 
2.4a Synthesis of compounds 
2.4b Cell lines and culture conditions 
2.4c MTT assay 
vii 
 
2.4d Florescence microscopy study 
2.4e Ethical Considerations for animal studies 
2.4f General procedure for systemic toxicity evaluation 
2.4g Anticancer efficacy of compound 2i in MIAPaCa-2 flank model 
2.5 NMR Spectra 
 
CHAPTER 3: Synthesis and Biological Evaluation of Chalcone Appended 
Cyanoacrylic acids 
3.1 Introduction 
3.1a Evolution of hallmarks of cancer: A focus on tumor metabolism 
3.1b Glycolysis and its relation to Warburg effect 
3.1c Monocarboxylic acid transporters (MCTs) and their importance in 
metabolism 
3.1d Mitochondrial pyruvate carriers 
3.1e CHC as MCT1 inhibitor  
3.1f SAR studies on CHC 
3.1g Other MCT1 inhibitors  
3.1j Pyrazole methylpropanoic acid derivatives as MCT4 inhibitors 
3.1k UK-5099 
3.1l Chalcones as a therapeutic agent 
3.1m Synthesis of Chalcones 
3.1n Chalcones as natural product and drug candidates: 
viii 
 
3.1o Chalcones as anticancer agents TUB091 and TUB099 
3.2 Results and Discussion: 
3.2a Synthesis of chalcone appended cyanoacrylic acid 
3.2b In vitro MTT based cell proliferation inhibition 
3.2c Seahorse XFe96® analyzer 
3.3 Conclusion 
3.4 Experimental 
3.4b Cell lines and culture conditions 
3.4c MTT assay 
3.4d Seahorse XFe96® assessment of glycolysis and mitochondrial 
respiration 
3.5 NMR Spectra 
References 
 
LIST OF SCHEMES 
Scheme 1.1: Synthesis of aminoindazole carboxylate 1.3.  
Scheme 1.2. Synthesis of ureido benzoic acids 1.4a-1.4k 
Scheme 1.3: Synthesis of carboxy indazole based diphenyl ureas 1.5a-1.5k.  
Scheme 1.4: Synthesis of aminoamide appended indazole ureas 
Scheme 2.1: Synthesis of piperidone curcuminoids as anticancer agents 
ix 
 
Scheme 2.2: Synthesis of azole based curcuminoids 
Scheme 2.3: Baylis-Hillman reaction 
Scheme 2.4: Conversion of Baylis-Hillman alcohols to acetates and bromides 
Scheme 2.5: SN2’ capability of BH acetates. 
Scheme 2.6: Synthesis of BH bromide derived peptidomimetics 
Scheme 2.7: Synthesis of 3-benzylidene-pyrrolidine-2,5-dione using BH bromide  
Scheme 2.8: Synthesis of Baylis-Hilman substituted imidazoles and triazoles 
Scheme 2.9: Synthetic schemes for biologically active Baylis Hillman derived 
symmetrical curcumin-like template 
Scheme 2.10. Structures of synthesized piperizinyl curcumin analogs 
Scheme 2.11: Synthesis of Baylis Hillman bromides 
Scheme 2.12. Synthesis of quaternary ammonium curcuminoids 
Scheme 2.13. Synthesis of morpholino quaternary ammonium salts 
Scheme 3.1: Knoevenagel condensation of substituted benzaldehydes with 
cyanoacetic acid to form CHC based derivatives 
x 
 
Scheme 3.2: A representative scheme for the synthesis of the library of N,N-
dialkyl amino CHC derivatives 
Scheme 3.3: The Claisen-Schmidt condensation to synthesize chalcones 
Scheme 3.4: Carbonylative Heck coupling reaction to synthesize chalcones 
Scheme 3.5: Sonogashira isomerization coupling to synthesize chalcones 
Scheme 3.6: Suzuki-Miyaura coupling reaction to synthesize chalcones 
Scheme 3.7: Synthesis of chalcone substituted cyanocinnamic acids 3d-3f 
LIST OF TABLES 
Table 1.1: MTT IC50 (µM) values of compounds 1.5a-k in, 4T1, GL261-luc2, 
MDA-MB-231 MIAPaCa-2, and WiDr cell lines 
Table 1.2: Cell proliferation inhibition of water soluble metabolically stable ureas   
Table 2.1: Cell proliferation inhibition activity of 2g-2m in MDA-MB-231, 
MIAPaCa-2 and 4T1 cell lines  
LIST OF FIGURES 
  Figure 1.1: Hallmarks of cancer 
xi 
 
Figure 1.2: Structure of anilino-pyrimidine template pharmacophore of EGFR 
inhibitors 
Figure 1.3: Structure of EGFR inhibitor Erlotinib 
Figure 1.4: Structure of EGFR inhibitor gefitinib 
Figure 1.5: Structure of EGFR inhibitor afatinib 
Figure 1.6: Structure of FGFR inhibitor AZD4547 
Figure 1.7: Structure of FGFR inhibitor infigratinib 
Figure 1.8: Structure of FGFR inhibitor ponatinib 
Figure 1.9: Clinically used VEGFR inhibitors for cancer therapy 
Figure 1.10: Structure of VEGFR inhibitor sunitinib 
Figure 1.11: structure of lenvatinib 
Figure 1.12: Structure of VEGFR inhibitor nintedanib 
Figure 1.13: Structure of pharmacologically important indazole template 
observed in new-generation VEGFR inhibitors 
Figure 1.14: Structure of VEGFR inhibitor axitinib 
xii 
 
Figure 1.15: Structure of VEGFR inhibitor pazopanib 
Figure 1.16. Structure of the diphenyl urea pharmacophore found in new-
generation multityrosine kinase inhibitors sorafenib and regorafenib 
Figure 1.17: Structure of sorafenib 
Figure 1.18: Structure of VEGFR inhibitor regorafenib 
Figure 1.19: Fused indazole-diphenyl urea-based structural template 
Figure 1.20. Structures of synthesized ureido benzoic acids 1.4a-1.4k.  
Figure 1.21. Structures of carboxy indazole diphenyl urea candidate compounds 
1.5a-1.5k 
Figure 1.22:  A CYP450 mediated metabolism and B lead compound 1.5i sites of 
metabolic stability and low water solubility.  
Figure 1.23: Graphical representation of Cell proliferation inhibition in different 
cell line 
Figure 1.24: Tube formation assay of compounds 1.5i and 1.8i in HUVEC cells 
Figure 1.25: Lead candidate compounds 1.5i, 1.7i and 1.8i for further in vivo 
studies 
 Figure 1.26: Systemic toxicity study of compounds in CD-1 mice 
xiii 
 
Figure 1.27: Anticancer efficacy study in colorectal adeno carcinoma WiDr flank 
model. (A)Tumor volumes (B) tumor weights 
Figure 1.28: Anticancer efficacy study in 4T1 tumor model   
Figure 2.1: Curcumin in its keto and enol form 
Figure 2.2 Therapeutic properties of curcumin 
Figure 2.3: Multiple modes of biological activity of curcumin 
Figure 2.4: Metabolites of curcumin 
Figure 2.5 Modification sites of curcumin, red circle highlights aromatic 
substitution, blue α, β unsaturation, green diketo and yellow denotes carbonyl 
Figure 2.6: Synthesis of carboxylic and ester based curcuminoids 
Figure 2.7: Structure of hydrazinocurcuminoid 
Figure 2.8: Structure of lead candidate compound with substitution on central 
carbon 
Figure 2.9: structure of modified mono ketones and alcohols of curcuminoid 
origin 
Figure 2.10: SN2, SN2’, and 1,4 addition capabilities of Baylis-Hillman bromides 
xiv 
 
Figure 2.11: structure of 1-134-83 
Figure 2.12: Structural template for various alky chain containing 
benzalkonium chlorides 
Figure 2.13: Structure of cetylpyridinium chloride 
Figure 2.14: Structure of ESC8 
Figure 2.15: Examples of mitochondrial targeting agents. 
Figure 2.16. Structures of synthesized quaternary ammonium curcuminoids 
Figure 2.17. Cell proliferation inhibition of compounds 2i-2m on 4T1, MDA-
MB-231, and MIAPaCa-2  
Figure 2.18. Fluorescence microscopy of MIAPaCa-2 cells treated with parent 
curcumin (10uM) and lead candidate 2i salt (10uM) for 24 hours. Note 
candidate 2i exhibited fluorescent characteristics when excited using a GFP 
filter set 
Figure 2.19: Systemic toxicity study of compound 2i 
Figure 2.20: Tumor growth inhibition study of 2i in MIAPaCa-2 flank xenograft 
study  
Figure 3.1: Metabolic symbiosis and Warburg effect in cancer cells  
xv 
 
Figure 3.2: Inhibition of MCT1 and/or MCT4 leads to a decrease in tumor growth 
Figure 3.3: Chemical structure of MCT1 inhibitor CHC 
Figure 3.4: The SAR study of the N,N-dialkyl/diaryl substituted CHC derivatives 
Figure 3.5: Structure of AZD3965  
Figure 3.6: Lead MCT4 inhibitor 2-((1-(2-chlorobenzyl)-5-(3-substituted 
phenyl)- 1H-pyrazol-3-yl)methoxy)-2-methylpropanoic acids 
Figure 3.7: Structure of UK-5099  
Figure 3.8: Structural template of chalcones 
Figure 3.9 Biological activities of Chalcones 
Figure 3.10: Examples of clinically explored chalcones 
Figure 3.11: Structure of xanthoangelol  
Figure 3.12: Structure of TUB091 and TUB099 
Figure 3.13: Reversible and irreversible units in chalcone cyanocinnamic acid 
structure 
Figure 3.14: Mitochondrial stress test in (A) 4T1, (B) MDA-MB-231 and (C) 
WiDr cell lines using compounds 3d-3e. The OCR values were calculated using 
xvi 
 
wave software. The average+SEM values of at least three independent 
experimental values were calculated. 
Figure 3.15: Maximal respiration in (A) 4T1, (B) MDA-MB-231 and (C) WiDr 
cell lines using compounds 3d-3f. The OCR values were calculated using wave 
software. The average+SEM values of at least three independent experimental 
values were calculated. 
Figure 3.16: ATP production in (A) 4T1, (B) MDA-MB-231 and (C) WiDr cell 
lines using compounds 3d-3f. The OCR values were calculated using wave 
software. The average+SEM values of at least three independent experimental 
values were calculated. 
Figure 3.17: Proton leak in (A) 4T1, (B) MDA-MB-231 and (C) WiDr cell lines 
using compounds 3d-3f. The OCR values were calculated using wave software. 
The average+SEM values of at least three independent experimental values were 
calculated. 
Figure 3.18: Spare respiratory capacity in (A) 4T1, (B) MDA-MB-231 and (C) 
WiDr cell lines using compounds 3d-3f. The OCR values were calculated using 
wave software. The average+SEM values of at least three independent 
experimental values were calculated. 
Figure 3.19: Glycolytic stress test in (A) 4T1, (B) MDA-MB-231 and (C) WiDr 
cell lines using compounds 3d-3f. The ECAR values were calculated using wave 
xvii 
 
software. The average+SEM values of at least three independent experimental 
values were calculated. 
Figure 3.20: Glycolysis in (A) 4T1, (B) MDA-MB-231 and (C) WiDr cell lines 
using compounds 3d-3f. The ECAR values were calculated using wave software. 
The average+SEM values of at least three independent experimental values were 
calculated. 
Figure 3.21: Glycolytic capacity in (A) 4T1, (B) MDA-MB-231 and (C) WiDr 
cell lines using compounds 3d-3f. The ECAR values were calculated using wave 
software. The average+SEM values of at least three independent experimental 
values were calculated. 
Figure 3.22: Glycolytic reserve in (A) 4T1, (B) MDA-MB-231 and (C) WiDr cell 
lines using compounds 3d-3f. The ECAR values were calculated using wave 
software. The average+SEM values of at least three independent experimental 
values were calculated. 
 
LIST OF ABBREVIATIONS 
MTR   multityrosine kinase 
TKR   tyrosine kinase receptors 
EGFR   epidermal growth factor receptor 
VEGFR  vascular endothelial growth factor receptor 
xviii 
 
FGFR   fibroblast growth factor receptor 
PDGFR  platelet derived growth factor receptor 
NSCLC  non-small cell lung cancer 
ATP   adenosine triphosphate 
MCT   monocarboxylic acid transporter 
SLC16   solute carrier 16 
kDa   kilo Dalton 
OxPhos  oxidative phosphorylation 
ER   estrogen receptor 
HER-2   human epidermal growth factor-2 
TNBC   triple negative breast cancer 
HIF-1α   hypoxia inducing factor 
NF-κB   nuclear factor kappa-light-chain-enhancer 
PR   progesterone receptor 
ROS   reactive oxygen species 
DNA   deoxyribonucleic acid 
CHC   α-Cyano-4-hydroxy cinnamic acid 
µmol   micromoles 
mM   millimolar 
IC50   inhibition of 50% of the activity or cell growth 
MPC   mitochondrial pyruvate carrier 
FDA   food and drug administration 
xix 
 
3-BPA   3-bromopyruvic acid 
mg/Kg   dosage in milligram per kilogram of mouse  
F   fluoro 
Br   bromo 
CN   cyano functional group 
NO2   nitro functional group 
CH3CN  acetonitrile 
NH4Ac  ammonium acetate 
OH   hydroxy functional group 
DMF   N,N-dimethylformamide 
POCl3   phosphorus (V) oxychloride 
R-Br   alkyl/allyl bromide 
H2O   water 
CNCH2COOH cyanoacetic acid 
HBr   hydrobromic acid 
H2SO4   sulfuric acid 
PBr3   phosphorous tribromide 
nM   nanomolar 
SEM   standard error of the mean 
SAR   structure-activity relationship 
K2CO3   potassium carbonate 
SRB   sulforhodamine-B 
xx 
 
MTT   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide 
MEM   minimum essential medium 
DMEM  Dulbecco’s minimum essential medium 
PI   propidium iodide 
FCM   flow cytometry 
acetyl CoA  acetyl coenzyme A 
DMSO   dimethyl sulfoxide 
ip   intraperitoneal 
bid   twice a day 
qd   once a day 
CYP   cytochrome P450 enzyme 
PBS   phosphate buffered saline 
EtOH   ethanol 
NaOH   sodium hydroxide 
GST   glycolysis stress test 
MST   mitochondrial stress test 
ECAR   extracellular acidification rate 
OCR   oxygen consumption rate 
mpH   milli pH 
pmol   pico moles 
FCCP   carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone 
xxi 
 
ETC   electron transport chain 
Dox   doxorubicin 
1H NMR  Proton (1H ) nuclear magnetic resonance spectrum 
13C NMR  Carbon (13C) nuclear magnetic resonance spectrum 
HRMS   high resolution mass spectrometer 
FBS   fetal bovine serum 
ATCC   American type cell culture 
TLC   thin layer chromatography 
HCl   hydrochloric acid 
Hz   Hertz 
MHz   Mega Hertz 
J   Coupling constant 
CDCl3   deuterated chloroform 
mA   milli amperes 






Chapter 1: Design of Novel Angiogenesis Inhibitors as Potential Anticancer 
Agents 
1.1 Introduction 
1.1a Cancer Heterogeneity and Hallmarks 
 Cancer research and treatment options have advanced tremendously over 
the past several decades and the development of novel and improved cancer 
therapies largely depends on a thorough understanding of the cellular, molecular 
and biochemical underpinnings of cancer progression. In this regard, cancer is a 
result of the accumulation of genetic and epigenetic mutations that drive normal 
cells to grow and divide uncontrollably.1 Frequently, these mutations arise in 
genes that control the cell cycle, DNA repair machinery, apoptosis, metabolism, 
proliferative signaling pathways, and many others where such mutations give rise 
to aggressive and malignant cell proliferation. Although cancer can vary widely 
by type, six major processes are conserved among all cancers which result in 
cancer sustenance and progression. Specifically, Hanahan and Weinburg have 
identified distinct hallmark characteristics which include the malignant cell’s ability 
to sustain proliferative signaling, evade growth suppressors, activate invasion 
and metastasis, enable replicative immortality, induce angiogenesis, and resist 
cell death (Figure 1.1).1 Recent literature reports have indicated that 
pharmacological disruption of pathways in cancer associated with angiogenesis 
and sustaining proliferative signaling may offer effective approaches to develop 
anticancer therapies.2–5 Based on the clinical success of such inhibitors, the 
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development of novel and improved inhibitors of angiogenesis and signaling 
pathways continue to be attractive targets for future cancer therapies.  
 
 
Figure 1.1: Hallmarks of cancer 
 
1.1bTyrosine Kinases and Their Role in Cancer 
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Tyrosine kinases, a subclass of protein kinase, are an important class of 
enzymes responsible for the transfer of a phosphate group from ATP to tyrosine 
residues of target proteins. As a result of phosphorylation, tyrosine kinases act 
as an "on" or "off" switch for many cellular functions including enzyme activity, 
sub cellular localization, signal transduction, cell division, and cell recruitment.6–9 
Tyrosine kinases are susceptible to mutations that result in hyperactivity and can 
lead to the development and progression of cancer.6–9 
Receptor tyrosine kinases are a subclass of kinases that have a primary role 
in transmembrane signaling. Currently, 58 receptor tyrosine kinases are known 
which have been categorized into 20 sub-families. Examples of receptor kinases 
are epidermal and fibroblast growth factor receptors (EGFR and FGFR) which 
play important roles in signaling cellular proliferation, differentiation, and 
apoptosis, and vascular endothelial growth factor receptors (VEGFR) responsible 
for stimulating angiogenesis.2,5,6,10–12 Receptor kinases consist of an extracellular 
domain, a transmembrane domain and an intracellular catalytic domain. The 
extracellular domain binds to specific ligands from outside the cell and allows the 
cells to send and receive signals from other cells. The transmembrane domain 
operates by anchoring the kinase to the membrane whereas the intracellular 
catalytic domain binds and phosphorylates the substrates.6 Binding of the 
extracellular domain results in structural rearrangements that turn on the 
intracellular domain. This activation can act in different ways such as, allowing 
for the binding of ATP or substrates. Functions of receptor tyrosine kinases are 
similar to other kinases but have an emphasis in cellular differentiation, 
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metabolism, adhesion, motility, and death.6 In oncogenesis, receptor kinases are 
altered by gene mutation or chromosome translocation often resulting in the 
overexpression or hyper activation of the receptor function - conferring  non-
regulated ligand-dependent cancer cell growth.6,7,9,13 
As mentioned, there are numerous sub-types of receptor tyrosine kinases that 
play specific roles in both normal cell function and malignant transformation. In 
this regard, the following sections will introduce the function of these different 
receptor sub-types and outline receptor tyrosine kinase inhibitors used for 
anticancer applications. 
1.1c Epidermal growth factor receptor (EGFR) family 
EGFR is a member of the ErbB subfamily of receptor tyrosine kinases and 
was the first member to be identified. The ErbB family is comprised of four 
receptor tyrosine kinases, Her1 (EGFR, ErbB1), Her2 (Neu, ErbB2), Her3 
(ErbB3), and Her4 (ErbB4).2,14 Changes in expression and function of ErbB 
kinases result in a variety of disease states where its deactivation can lead to 
neurodegenerative diseases, such as multiple sclerosis, Alzheimers, and 
Parkinson’s, while its hyper activation correlates with formation and progression 
of solid tumors.2,10,14–16 Specifically, ErbB1 and ErbB2 have been found to be 
overexpressed in many cancers including gliomas, breast, ovarian, bladder, and 
non-small-cell lung carcinoma (NSCLC).10,14,16 Due to their important role in 
cancer progression, numerous drug candidates have undergone pre-clinical 
investigation. It has been found that inhibition of EGFR often results in cytostatic 
effects as opposed to apoptosis in vitro. However, literature reports indicate that 
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in vivo inhibition of EGFR results in tumor regression and can be explained by 
several factors including both cytostatic and apoptotic effects.  Interestingly, 
EGFR inhibitors have been shown to act on other factors such as angiogenesis 
and are typically supplemented with anti-VEGFR therapies for cancer 
treatment.11,17 In this regard, numerous EGFR inhibitors have been developed 
which will be outlined in the following sections.   
1.1d EGFR Inhibitors  
Two important classes of EGFR inhibitors include synthetic small molecules and 
antibody-based therapies. Throughout the development of small molecule 
inhibitors, pre-clinical investigation has led to the optimization of the important 
anilino-pyrimidine pharmacophore for EGFR binding and inhibition (Figure 1.2). 
In this regard, the following potent synthetic EGFR inhibitors contain a conserved 
anilino-pyrimidine template. These inhibitors include reversible inhibitors erlotinib 
gefitinib, and irreversible inhibitor afatinib (Figure 1.3, 4, and 5).  
 
Figure 1.2: Structure of anilino-pyrimidine template pharmacophore of EGFR 
inhibitors. 
 Erlotinib is a receptor tyrosine kinase inhibitor marketed by Genentech, 
which acts on the epidermal growth factor receptor (EGFR). The IC50 of erlotinib 
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for EGFR is 2nM in cell free assays.18 Erlotinib inhibits growth of a panel of 
NSCLC cell lines including A549, H322, H3255, H358 H661, H1650, H1975, 
H1299, H596 with IC50 values in the low nanomolar range.19 Currently, it is used 
to treat NSCLC, pancreatic cancer and several other types of cancer.2,17,20 
Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, 
which is a mutant form of tyrosine kinase JAK2 found in most patients with 
polycythemia vera.21 Further investigations are underway to study the potential 




Figure 1.3: Structure of EGFR inhibitor Erlotinib 
 
 Gefitinib is a receptor tyrosine kinase inhibitor marketed by AstraZeneca, 
which acts on the EGFR by binding the ATP binding site (Figure 1.4). Gefitinib 
was the first selective inhibitor of EGFR. Similar to erlotinib, gefitinib also shows 
inhibition properties on multiple cancer types including NSCLC.22,23 In 2003, 
gefitinib was approved as monotherapy for the treatment of patients with locally 
advanced or metastatic NSCLC after failure of both platinum-based and 
docetaxel chemotherapies. However, in 2005 this approval was rescinded due to 
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the lack of ability to extend the life of patients.  In the meantime gefitinib received 
approval in numerous other countries and in 2015 was reapproved for clinical use 
on NSCLC, this time as a first-line of treatment.24  
 
Figure 1.4: Structure of EGFR inhibitor gefitinib 
 Afatinib is an irreversible receptor tyrosine kinase inhibitor marketed by 
Boehringer Ingelheim, which acts on EGFR (Figure 1.5). It is a direct competitor 
of erlotinib for the treatment of NSCLC.  One limitation of EGFR targeted 
therapies includes acquired resistance due to genetic mutations. T790M is a 
gatekeeper mutation of EGFR and results in over 50% of acquired resistance of 
tyrosine kinase inhibitors through a substitution of threonine with methionine at 
position 790 of exon 20. In addition to being an irreversible inhibitor, afatinib is 
one of the therapies that can treat patients with T790M mutations that do not 





Figure 1.5: Structure of EGFR inhibitor afatinib 
 
1.1e Fibroblast growth factor receptor (FGFR) family 
FGFRs are a class of receptor tyrosine kinases that have function similar to 
VEGFR. FGFRs bind over 20 different growth factor ligands making it one of the 
largest among the receptor tyrosine kinase families.12,25 They play an important 
role during embryonic development, angiogenesis, wound healing, cell 
proliferation and differentiation.12,25 It has also been reported that upregulation of 
FGFR occurs as a resistance mechanism to anti-VEGF therapies.17,18,23 In 
addition to their role in angiogenesis, they are also speculated to have a major 
role in another hallmark of cancer, sustaining proliferative signaling.1,26 This 
signaling occurs through downstream activation of PI3K/AKT/mTOR and 
RAS/RAF/ERK pathways.26 Targeting of FGFRs compliment EGFR and VEGFR 
therapy resulting in reduction of angiogenesis as well as inhibition of proliferative 
signaling.17,18,23 
AZD4547 is a potent inhibitor of FGFR-1,2 and 3 with an IC50 < 5nM. 
AZD4547 was shown to inhibit proliferation in a dose-dependent manner in 
several cancer cell-lines that are known to overexpress fibroblast growth 
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factor (FGF) receptors (Figure 1.6).27–29 In KMS11, KG1a and SUM52PE cell-
lines, AZD4547 inhibited FGFR tyrosyl phosphorylation and the 
phosphorylation of the downstream signaling molecules p42/p44MAP 
kinases.27 AZD4547 has undergone clinical trials in previously treated patients 
with FGFR altered stage IV squamous cell lung cancer and showed acceptable 
safety but minimal activity. 28 
 
Figure 1.6: Structure of FGFR inhibitor AZD4547. 
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Infigratinib is potent and selective inhibitor of FGFR1/2/3 with IC50 of ~1.0 
nM of each FGFR.30 Infigratinib also has good potency against VEGFR2 and low 
levels of activity against other tyrosine kinases (Figure 1.7). Infigratinib induces 
apoptosis and vessel normalization and improves the overall survival of mice 
bearing FGFR-driven HCCs and has shown synergy with microtubule-
depolymerizing agent vinorelbine.30–32 Currently, infigratinib is undergoing phase 
III clinical trials as a first line of treatment for cholangiocarcinoma.  
 
Figure 1.7: Structure of FGFR inhibitor infigratinib.  
Ponatinib is a novel, potent multi-target inhibitor of VEGFR2, FGFR1, and 
PDGFRα with activities ranging in 0.5 to 5 nM (Figure 1.8).33 Additionally, 
ponatinib is a potent inhibitor of Bcr-Abl tyrosine kinase with T315I mutations. 
The T315I mutation confers resistance in cells as it prevents other Bcr-Abl 
inhibitors from binding to the Abl kinase.34,35  It is clinically indicated for treating 
accelerated phase chronic myologenic leukemia, acute lymphoblastic leukemia, 




Figure 1.8: Structure of FGFR inhibitor ponatinib. 
1.1f Vascular endothelial growth factor receptor (VEGFR) family  
 VEGFRs are typical tyrosine kinase receptors (TKRs) comprised of three 
domains, an extracellular domain, a transmembrane domain, and a cytoplasmic 
domain. VEGFRs are a sub family of platelet-derived growth factor receptors 
(PDGFRs). VEGFRs differ from PDGFRs in the number of Ig-like domains on the 
extracellular portion and the intracellular domain contains the same motifs 
resulting in different downstream signaling.26,36 VEGFR exists in three forms: 
VEGFR-1, VEGFR-2, and VEGFR-3. The function of VEGFR-1 is to act as a 
“dummy” receptor and modulate activators of VEGFR-2. VEGFR-2’s major role 
is proangiogenic signaling. The function of VEGFR-3 is not clearly understood; 
however, literature reports indicate it may have a role in lymphangiogenesis.3,37 
VEGF and VEGFRs play a major role in the recruitment of endothelial cells to 
form a network of capillaries. Overexpression of VEGF and VEGFRs have been 
linked to recurrence, metastasis, and poor prognosis in breast, colon, renal, 
bladder, and head and neck cancers.10,11,38,39 
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  Owing to the importance of VEGFR in cancer progression, numerous 
synthetic small molecules have been developed as VEGFR inhibitors targeting a 
wide variety of cellular processes in numerous cancer types (Figure 1.9).  
 
Figure 1.9: Clinically used VEGFR inhibitors for cancer therapy.  
VEGFR inhibitors 
Sunitinib is a potent ATP-competitive inhibitor of VEGFR2 and PDGFRβ 
with IC50 values of 9 nM and 8 nM in cell free assays (Figure 1.10).40 It also 
exhibits good activity against FGFR-1 and EGFR amongst other kinases.41 
Sunitinib has been approved for the treatment of renal cell carcinoma and 




Figure 1.10: Structure of VEGFR inhibitor sunitinib.  
 
Lenvatinib in a potent multi receptor tyrosine kinase inhibitor with inhibition 
of VEGFR1/2/3, FGFR1/2/3/4, PDGFRα, KIT, and RET (Figure 1.11).40 
Lenvatinib is indicated for the treatment of patients with locally recurrent or 
metastatic, progressive, radioactive iodine refractory differentiated thyroid 
cancer.44,45 Typically, patients with thyroid cancer have very high rates of survival 
except in patients with radioactive iodine refractory differentiated thyroid cancer 
making lenvatinib especially useful in this sub set of patients. Lenvatinib has 
recently received approval as a second-line of defense for advanced renal cell 
carcinomas.  
 
Figure 1.11: structure of Lenvatinib 
 
Nintedanib is a potent receptor tyrosine kinase inhibitor 
for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50 values ranging from ~10-
100 nM.40 Inhibition occurs through binding of ATP binding site resulting in 
decreased intracellular signaling (Figure 1.12). Nintedanib also inhibits the 
following non receptor tyrosine kinases, Lck, Lyn, and Src.46  It has received 
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approval for use as a combination agent with docetaxel as a second line 
treatment for advanced, metastatic, or recurring NSCLC. In addition to cancer, 
nintedanib has been approved for use in idiopathic pulmonary fibrosis.47 FGFR, 
PDGFR, and VEGFR have been implicated in the pathogenesis of idiopathic 
pulmonary fibrosis making multityrosine kinase inhibitors attractive candidates for 
treatment.  
 
Figure 1.12: Structure of VEGFR inhibitor nintedanib.  
 
 
Design of novel indazole based VEGFR inhibitors: New-generation VEGFR 
inhibitors. 
Nitrogen‐containing heterocycles are pharmacologically important 
scaffolds, and they are present in numerous FDA-approved and commercially 
available drugs.48–50 Indazoles are a class of heterocycles comprised of a 
benzene fused to a pyrazole and can exist as 1H‐indazole, 2H‐indazole, and 3H‐
indazole (Figure 1.12).48–50 Indazoles exhibit a wide range of biological 
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properties such as anti‐inflammatory, antimicrobial, anti‐HIV, antihypertensive, 
and anticancer activities.48–50 Specifically, pazopanib and axitinib are tyrosine 
kinase inhibitors that are in clinical use for the treatment of various cancers that 
include indazole and diphenyl urea based structural template (Figure 1.12-17).51–
56 
 
Figure 1.13: Structure of pharmacologically important indazole template 
observed in new-generation VEGFR inhibitors. 
Axitinib is a multi-target inhibitor developed by Pfizer as an inhibitor 
of VEGFR1/2/3 and PDGFRβ with IC50 values ranging from 0.1-2.0 nM (Figure 
1.14).57 Axitinib has been approved by FDA for renal cell carcinoma after showing 
an increase of progression free survival.55–57 Investigations of axitinib are ongoing 
for the treatment of second-line defense of kidney, thyroid, and pancreatic 
cancers. Axitinib has also been evaluated in chronic myeloid leukemias with a 
mutated BCR-ABL1 gene that are resistant to other tyrosine kinase inhibitors 





Figure 1.14: Structure of VEGFR inhibitor axitinib. 
 
Pazopanib is a novel indazole based multi-target inhibitor of VEGFR1/2/3, 
PDGFR, and FGFR, exhibiting IC50 values between 10 and 150 nM (Figure 
1.15).59 Pazopanib is developed by GlaxoSmithKline and received approval for 




Figure 1.15: Structure of VEGFR inhibitor pazopanib. 
 




Figure 1.16. Structure of the diphenyl urea pharmacophore found in new-
generation multityrosine kinase inhibitors sorafenib and regorafenib.  
Sorafenib is a diphenyl urea based multi tyrosine kinase inhibitor with potent 
activity in the 5-100nM range against Raf, VEGFR, PDGFR, and cKit marketed 
by Bayer (Figure 1.17).60,61 Sorafenib’s novelty is its ability to simultaneously 
target the Raf/Mek/Erk pathway. Sorafenib has been indicated for the treatment 
of advanced renal cell carcinoma, gastrointestinal stromal tumors, 
hemangiosarcoma, unresectable hepatocellular carcinoma, locally recurrent 
refractory to radioactive iodine treatment thyroid carcinoma, and metastatic 
refractory to radioactive iodine treatment thyroid carcinoma.55,62–66 
 
Figure 1.17: Structure of sorafenib. 
 
Regorafenib is an orally bioavailable diphenyl urea based multi tyrosine kinase 
inhibitor marketed by Bayer. Regorafenib is structurally very similar to sorafenib 
with increased potency and pharmacokinetic/dynamic properties. Inhibition of 
Raf, VEGFR, PDGFR, and cKit range from 1-25nM (Figure 1.18).67,68 
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Regorafenib is up to 83% bioavailable with a half-life  of 20-30 hours compared 
to sorafenib with only 49% bioavaibility.69  Regorafenib is indicated for the 
treatment of patients with metastatic colorectal cancer who have been previously 
treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based anti-VEGF 
chemotherapy, and, if KRAS wild type, an anti-EGFR therapy. In addition to 
metastatic colorectal cancer, regorafenib has also received approval for 
metastatic gastrointestinal stromal tumor, locally advanced gastrointestinal 
stromal tumor, refractory, unresectable gastrointestinal stromal tumors, locally 
recurrent or metastatic, progressive differentiated thyroid carcinoma refractory to 
radioactive iodine treatment, and advanced hepatocellular carcinoma.5,63,67–74 
 




1.2: Results and discussion 
1.2a Synthesis of carboxy indazole diphenyl ureas as anticancer agents 
 Owing to the previous pharmacological track-record of both indazole and 
diphenyl urea structural templates toward VEGFR inhibition, we sought to 
synthesize novel fused indazole-diphenyl urea-based drug candidates (Figure 
1.19).  
 
Figure 1.19: Fused indazole-diphenyl urea-based structural template 
We started the synthesis of indazole derivatives by using commercially available 
indazole 3-carboxylic acid. The acid was treated with thionyl chloride in ice-cold 
methanol to obtain 1H-indazole-3-carboxylate 1. This product was further reacted 
with 1-fluoro-4-nitrobenzene in the presence of potassium carbonate in DMSO to 
get the nitro-phenyl indazole carboxylate 2.  The nitro group in 2 was then 
reduced with palladium carbon and ammonium formate to obtain aminoindazole 





Scheme 1.1: Synthesis of aminoindazole carboxylate 1.3.  
We then synthesized ureido benzoic acids 1.4a-1.4k, 4-(3-phenylureido)benzoic 
acid, 4-(3-(2-chlorophenyl)ureido)benzoic acid, 4-(3-(4-tolyl)ureido)benzoic acid, 
4-(3-(4-(trifluromethyl)phenyl)ureido)benzoic acid, 4-(3-(4-
methoxyphenyl)ureido) benzoic acid, 4-(3-(4-fluorophenyl)ureido)benzoic acid, 
4-(3-(4-chlorophenyl) ureido)benzoic acid, 4-(3-(2,4-
dichlorophenyl)ureido)benzoic acid, 4-(3-(4-chloro-3-(trifluoromethyl) 
phenyl)ureido)benzoic acid, 3,4,5-OCH3 4-(3-(3,4,5-trimethoxy 
phenyl)ureido)benzoic acid, 4-(3-cyclohexylureido)benzoic acid by reacting 4-
aminobenzoic acid with corresponding isocyanates in THF in excellent yields 




Scheme 1.2. Synthesis of ureido benzoic acids 1.4a-1.4k 
  
Figure 1.20. Structures of synthesized ureido benzoic acids 1.4a-1.4k.  
Next, we coupled the amine group in indazole unit and the corresponding 
ureido benzoic acid in DMF with EDC and HOBT overnight to form carboxy 
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indazole based diphenyl ureas (1.5a-1.5k) in good to moderate yields (Scheme 
1.3, Figure 1.21). 




Figure 1.21. Structures of carboxy indazole diphenyl urea candidate compounds 
1.5a-1.5k 
1.2b Cell proliferation study of compounds 1.5a-1.5k using MTT assay 
After synthesizing compounds 1.5a-1.5k we evaluated these compounds 
for cell proliferation inhibition properties to explore their potential as anticancer 
agents. Initial in vitro cell proliferation studies of the synthesized compounds 
1.5a-1.5k were carried out using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. This colorimetric assay measures the 
reduction of MTT to formazan by cellular mitochondrial reductase as a measure 
of cell viability.  
24 
 
For this assay, we utilized five cell lines including murine metastatic breast 
cancer cell line 4T1, murine glioma cell line GL261-luc2, human triple negative 
breast cancer cell line MDA-MB-231, human pancreatic cancer cell line 
MIAPaCa-2, and human colorectal adenocarcinoma cell line WiDr (Table 1.1). 
In 4T1 cell line, compounds 1.5a-1.5k showed IC50 values between 0.9 
and 5.0 µM, whereas 4-methoxy and 3, 4, 5-trimethoxy derivatives 1.5e and 1.5j 
did not exhibit IC50 values up to the maximum concentration tested of 50 µM. 
In GL261-luc2 cell line, compounds 1.5a-1.5k showed IC50 values 
between 0.8 and 3.7 µM, whereas 4-methoxy and 3, 4, 5-trimethoxy derivatives 
1.5e and 1.4j exhibited IC50 values up to 24.8 and 32.2 µM, respectively.  
In MDA-MB-231cell line, compounds 1.5a-1.5k exhibited IC50 values 
between 0.5 and 3.7 µM, whereas 3, 4, 5-trimethoxy derivative 1.5j exhibited IC50 
values up to 26.4 µM.  
In MIAPaCa-2 cell line, compounds 1.5a-1.5k showed IC50 values 
between 3.1 and 11.0 µM, whereas 2-chloro derivative 1.5b exhibited IC50 value 
up to 30.2 µM and 4-methoxy and 3, 4, 5-trimethoxy derivatives 1.5e and 1.5j did 
not exhibit IC50 values up to 50µM. 
In WiDr cell line, compounds 1.5a-1.5k showed IC50 values between 0.6 
and 8.1 µM, whereas 4-methoxy 1.5e did not exhibit toxicity up to 50 µM 






Based on the results obtained from cell proliferation inhibition studies, we 
selected compound 1.5i as a lead derivative. 1.5i showed consistently exhibited 
good potency amongst the lowest IC50 values against all the tested cell lines 
(Table 1.1).  
Table 1.1: MTT IC50 (µM) values of compounds 1.5a-k in, 4T1, GL261-luc2, 
MDA-MB-231 MIAPaCa-2, and WiDr cell lines. 
Compound 4T1 GL261-luc2 MDA-MB-231 MIAPaCa-2 WiDr 
1.5a 1.9±0.4 3.1±0.5 1.8±0.1 11.0±2.0 1.1±0.3 
1.5b 1.4±0.4 3.7±0.2 2.1±0.3 30.2±1.0 2.7±0.5 
1.5c 0.9±0.4 0.8±0.1 0.5±0.2 4.8±0.4 8.1±0.3 
1.5d 1.8±0.4 2.8±1.5 1.2±0.5 5.9±0.5 5.6±0.4 
1.5e >50.0 24.8±1.0 4.9±0.8 >50.0 >50.0 
1.5f 4.8±1.7 3.1±0.4 4.3±0.5 3.1±0.4 0.6±0.1 
1.5g 1.4±0.1 1.5±0.3 7.0±0.9 4.1±0.2 1.7±1.1 
1.5h 1.1±0.2 1.4±0.1 1.3±0.1 5.2±0.5 3.7±1.5 
1.5i 3.6±1.2 2.6±0.5 3.7±0.8 4.6±0.8 1.3±0.2 
1.5j >50.0 32.2±4.2 >50.0 >50.0 26.6±0.7 
1.5k 5.0±0.4 3.1±1.4 26.4±1.4 6.5±0.7 1.2±0.4 








1.2c Synthesis of amido indazole diphenyl ureas as anticancer agents:  
Other important considerations of small molecule drug development include 
metabolic stability and water solubility. Cytochrome P450 (CYP450) enzymes are 
responsible for a wide variety of oxidation reactions on xenobiotics. Specifically, 
unsubstituted phenyl rings are highly susceptible to CYP450-mediated oxidation 
and rapid elimination (Figure 1.22). From a structural and metabolic perspective, 
compound 1.5i also has multiple sites on the phenyl rings blocked with chlorine 
and trifluoromethyl which could slow down CYP450 oxidation resulting in 
metabolic stability (Figure 1.22). However, due to the high carbon content and 
hydrophobic characteristics of compounds, they did not exhibit good water 




Figure 1.22:  A CYP450 mediated metabolism and B lead compound 1.5i sites 
of metabolic stability and low water solubility.  
In this regard, we hydrolyzed the methyl ester of compound 1.5i by dissolving it 
in DMSO and heating in the presence of sodium hydroxide. Upon evaluation of 
this new compound, we found that the activity of acid 1.6i was lost in all the cell 
lines up to a concentration of 50 µM. We hypothesized that the carboxylic acid 
homolog 1.6i became ionized limiting its ability to cross the cell membrane. In 
this regard, we sought to improve the hydrophilicity of compound 1.5i further by 
synthesizing two different aminoamide derivatives.  
 
Scheme 1.4: Synthesis of aminoamide appended indazole ureas 
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The first derivative was prepared by dissolving 1.6i in DMF and adding 
EDC/HOBT with N,N-dimethyl ethylene diamine to afford 1.7i. The second 
derivative was prepared in a similar fashion instead using N-methylpiperazine, 
affording 1.8i (Scheme 1.4). 
 
 
1.2d Cell proliferation study of compounds 1.6i, 1.7i and 1.8i using MTT assay:  
These compounds 1.7i and 1.8i exhibited enhanced solubility compared to the 
parent compound 1.5i. Evaluation of cell proliferation inhibition resulted in 
comparable activity on all five cells lines of the parent compound 1.5i (Table 1.2). 
These amino amide derivatives exhibited improved solubility properties.   
 
Table 1.2: Cell proliferation inhibition of water soluble metabolically stable ureas   
Compound 4T1 GL261-luc2 MDA-MB-231 MIAPaCa-2 WiDr 
1.6i >50.0 >50.0 >50.0 >50.0 >50.0 
1.7i 5.5±1.2 0.8±0.1 2.7±0.4 2.8±0.3 1.3±0.1 
1.8i 6.4±0.2 1.3±0.3 3.3±0.3 10.2±0.5 3.1±0.7 
 
A comparative analysis of all the synthesized compounds 1.6i-1.8i were shown 

























































































































































































































































































































Figure 1.23: Graphical representation of Cell proliferation inhibition in different 
cell line 
 
1.2e Endothelial Cell Tube Formation Assay: 
We hypothesized that our synthesized compounds work by inhibiting 
angiogenesis similar to that sorafenib and regorefanib. Therefore, we evaluated 
the ability of compounds 1.5i and 1.8i to inhibit the formation of tubes in an 
endothelial cell line, HUVEC. For this assay, we coated plates with Matrigel Matrix 
and added compound 1.5i and 1.8i at concentrations of 1 μM and 5 μM. After a 
period of 18-24 hours, we added Calcein AM for fluorescent labeling. We then 
acquired fluorescent images and measured the length of tubes as a measure of 
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Figure 1.24: Tube formation assay of compounds 1.5i and 1.8i in HUVEC cells 
 











1.2f Systemic toxicity evaluation of 1.5i, 1.7i and 1.8i in CD-1 mice 
Compounds 1.5i, 1.7i and 1.8i showed inhibition of cellular proliferation at 
low µM concentrations against five cell lines, inhibition of tube formation in 
HUVEC cells, and good water solubility. We then evaluated the systemic toxicity 
of the lead compounds in healthy CD-1 mice. We chose inhibitors 1.5i, 1.7i and 
1.8i as lead derivatives (Figure 1.25) for the further preclinical development as 
they were well tolerated in the mice. 
 
 
Figure 1.25: Lead candidate compounds 1.5i, 1.7i and 1.8i for further in vivo 
studies 
The compounds were dissolved in a formulation comprised of 10% DMSO, 
10% PEG, 40% Kolliphor (18.8% wt/volume), and 40% water to achieve a 
concentration where a dosage of 25 mg/Kg could be given in such a way that a 
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20g mouse would receive a 0.20mL injection. CD-1 mice were randomly assigned 
into groups (n = 6 mice per group) with similar average body weights and then 
were treated with compound 1.5i at 25 mg/Kg, ip, bid, compound 1.7i at 25 
mg/Kg, ip, bid, compound 1.8i at 25 mg/Kg, ip, qd, or vehicle (same as vehicle). 
At the end of the study, the treatment groups did not show any visible toxic effects 
such as abnormal grooming, hunchback, and morbidity. The treatment groups 
had no significant differences in body weights compared to control groups 
(Figure 1.26). 
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Figure 1.26: Systemic toxicity study of compounds in CD-1 mice 
As the lead compounds 1.5i, 1.7i, and 1.8i were well tolerated in mice, we 
next evaluated these compounds for anticancer efficacy on WiDr xenograft 
model. For this study, female athymic nude mice were utilized. Mice were injected 
with 5 x 106 cells suspended in 1:1 mixture of PBS-matrigel. The treatment was 
initiated after tumors reached a mean volume of 150 mm3. Mice were randomly 
assigned in to groups (n = 6 mice per group) and mice in groups 1-3 were treated 
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with 1.5i, 1.7i, and 1.8i, respectively, at 25mg/Kg, i.p, once daily, for 14 days. 
Tumor volume was monitored every 2-3 days (Figure 1.27) and starting on day 
12, compound 1.8i showed statistically significant tumor growth reduction of (P < 
0.05) 47% and 39% compared to control and oxaliplatin, respectively. At the 
conclusion of the study, mice were euthanized, tumors were resected and 
weighed. Once again, compound 1.8i showed significant reduction of (P < 0.05) 
43% and 38% compared to control and oxaliplatin groups, respectively (Figure 
1.26B). This data supports the in vitro results and our hypothesis about the lability 
of methyl ester and we did not observe any significant reduction of compounds 
1.5i or 1.8i by volume or weight. 
 
1.2g In vivo anticancer efficacy studies using lead candidate compounds:  
Anticancer efficacy of compounds 1.5i, 1.7i, and 1.8i in colorectal adeno 
carcinoma WiDr flank model 
 We then evaluated the lead candidate compounds 1.5i, 1.7i, and 1.8i for 
in vivo efficacy in colorectal adenocarcinoma WiDr tumor flank model. We 
selected WiDr cell line because tyrosine kinase inhibitors have been FDA 
approved for clinical use to treat colorectal cancers and this cell line readily forms 
aggressive tumors in nude mice. Compound 1.5i was selected for in vivo 
anticancer efficacy study because of its good cytotoxicity and presumed 
metabolic stability of the urea. Compound 1.7i and 1.8i were also selected due 
to their increased water solubility and metabolic stability of the amide that 
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replaced the ester. We also included oxaliplatin, a clinically used anti-cancer 
agent. 
 5 x 106 WiDr cells in a 1:1 mixture of Matrigel:PBS were inoculated onto 
the flank of female BALB/c nude mice. After the average tumor volume reached 
~125 mm3, mice were randomly assigned into 5 groups (n = 6 mice per group). 
groups 1-3 were treated with 1.5i, 1.7i, and 1.8i, respectively, at 25mg/Kg, i.p, 
once daily, for 14 days. Group 4, our positive control was treated with oxaliplatin 
at 10 mg/Kg twice per week for 14 days. Group 5 was assigned as a control group 
and was treated with our vehicle. Body weights and tumor volume were 
measured every 2-3 days and after 14 days of treatment, mice were euthanized, 
and tumors were resected and weighed.  
From this study 1.8i showed a statistically significant reduction of tumor 
volume (P < 0.05) 47% and 39% compared to control and oxaliplatin respectively. 
At the conclusion of the study, mice were euthanized, tumors were resected and 
weighed. Once again 1.8i showed significant reduction of (P < 0.05) 43% and 
38% control and oxaliplatin respectively. Oxaliplatin was not able to significantly 
reduce the tumor burden. Supporting our in vitro results and hypothesis about the 
lability of methyl ester, we did not see any significant reduction of compounds 
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Figure 1.27: Anticancer efficacy study in colorectal adeno carcinoma WiDr flank 
model. (A)Tumor volumes (B) tumor weights 
 
3.7.3 Anticancer efficacy of lead candidate compound 1.8i in syngeneic 
4T1-luc2 flank model: 
Since tyrosine kinase inhibitors have FDA approval for multiple cancer 
types and have been used in the clinic, we evaluated the efficacy of lead 
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compounds against 4T1 murine tumor model system. 4T1 is an aggressive 
murine cancer known to be highly metastatic to liver, lungs, bone, and brain.  
Since compound 1.5i and 1.7i did not show significant reduction in WiDr model, 
we chose compound 1.8i as a lead candidate for tumor efficacy evaluation in 4T1 
model. Once again, compound 1.8i was compared against a positive and 
negative control. For the positive control, we chose to use doxorubicin as it is a 
clinical drug approved for breast cancer treatment.  
The flank of female BALB/c mice (4 weeks old) were injected with 1 × 105 
cells 4T1 cells. Mice were randomized in to 3 groups (n = 6 mice per group) and 
due to the aggressiveness of this model, we began treatment of compounds after 
48 hours of tumor inoculation. Mice in groups 1 were administered with lead 
molecule 1.8i at a dosage of 25 mg/Kg, ip, and doxorubicin was administered at 
0.5 mg/Kg, i.p. five days a week as a positive control in group 2. Mice in group 3 
were used as a control group and were administered with vehicle. At the end of 
the study (day-14 of treatment), mice were euthanized, and tumor samples were 
retrieved and weighed. Compound 1.8i exhibited a significant reduction in tumor 











































 In conclusion, we synthesized several carboxy indazole based diphenyl 
ureas. Evaluation of these inhibitors showed good cell proliferation inhibition on 
five cell lines of different cancer types, murine metastatic breast cancer cell line 
4T1, murine glioma cell line GL261-luc2, human triple negative breast cancer cell 
line MDA-MB-231, human pancreatic cancer cell line MIAPaCa-2, and human 
colorectal adenocarcinoma cell line WiDr. Furthermore, we evaluated lead 
compounds 1.5i and 1.8i for their potential to inhibit tube formation in HUVEC 
cells. We found that compounds 1.5i and 1.8i significantly reduced the length of 
the tubes. After demonstrating inhibition of cellular proliferation and the ability of 
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endothelial cells to assemble in tube we translated to in vivo models. For this we 
first evaluated systemic toxicity in CD-1 mice for compounds 1.5i, 1.7i, and 1.8i 
and found no significant body weight changes or noticeable behavioral changes.  
Anticancer efficacy studies in colorectal adenocarcinoma cell line WiDr and 
metastatic murine breast cancer 4T1 flank models showed that the lead 
candidate compound 1.8i provided anticancer efficacy at a clinically relevant 
dosage of 25mg/Kg ip. Further investigations of these compounds can focus on 





1.4a Chemicals and methods of compound characterization 
Indazole methyl carboxylate, 4-fluronitrobenzene, EDC, and HOBT were 
acquired from Fisher Scientific, isocyantes, cyanoacetic acid, and piperidine were 
purchased from Millipore-Sigma, All other chemicals were of reagent grade 
quality and purchased from Millipore-Sigma. The 1H- and 13C-NMR spectra were 
recorded on a Varian Oxford-500 spectrometer. High-resolution mass spectra 
(HRMS) were recorded using a Bruker BioTOF II ESI mass spectrometer. 
Elemental analysis (CHN) results were obtained from Atlantic Microlab services.  
1.4b Synthesis of methyl 1-(4-nitrophenyl)-1H-indazole-3-carboxylate (1.2): 
Synthesis of the precursor 1.1 was conducted by taking commercially available 
methyl 1H-indazole-3-carboxylate (10 mmol) and dissolving it in DMSO 50mL. 1-
fluoro-4-nitrobenzene (11 mmol) was added to the solution. Potassium carbonate 
(30 mmol) was added to the solution, and the mixture was heated to 120 °C for 
4hr. After cooling to room temperature, the solution was poured over ice. The 
resulting pale yellow solid 1.2 was allowed to dry and then stirred in hexanes 




1H NMR (500 MHz, DMSO-d6) δ 8.45 (d, J = 9 Hz, 2H), 8.22 (d, J = 8 Hz, 1H), 
8.14 (d, J = 9 Hz, 2H), 8.05 (d, J = 9 Hz, 1H), 7.66 (t, J = 8 Hz, 1H), 7.51 (t, J = 8 
Hz, 1H), 3.99 (s, 3H) 
13C NMR (126 MHz, DMSO-d6) δ 162.3, 146.2, 144.2, 139.9, 138.2, 129.3, 125.8, 
125.1, 124.6, 123.5, 122.5, 112.2, 52.7 
1.4c Synthesis of methyl 1-(4-aminophenyl)-1H-indazole-3-carboxylate: 
Synthesis of 1.3 was conducted by taking 1.2 (10 mmol) and dissolving it in THF 
50mL.  Pd/C (0.5 g, 10% Pd) and ammonium formate (30 mmol) was added and 
the mixture was refluxed for 4hr. After completion of the reaction the mixture was 
filtered through silica gel and solution was evaporated under reduced pressure 
to afford the pure product. 
 
1H NMR (500 MHz, DMSO-d6) δ 8.16 (d, J = 8 Hz, 1H), 7.67 (d, J = 9 Hz, 1H), 
7.5 (t, J=7 Hz, 1H), 7.36 - 7.40 (m, 3H), 6.68 - 6.82 (m, 2H), 5.53 (s, 2H), 3.95 (s, 
3H) 
13C NMR (126 MHz, DMSO-d6) δ 162.9, 149.6, 140.3, 135.0, 127.9, 127.6, 125.4, 
124.0, 123.8, 121.8, 114.4, 111.8, 52.2 
1.4d Synthesis of 4-(3-phenylureido)benzoic acid (1.4a): Synthesis of 1.4a was 
conducted by taking  4-Aminobenzoic acid (10 mmol)  and dissolving it in THF 
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(25mL) and a solution of phenyl iscocyante (10mmol) in THF (25mL) was added. 
After 30-60min the resulting solid was filtered and washed with additional portion 
of THF (10mL) to afford the pure product.  
4-(3-(2-chlorophenyl)ureido)benzoic, 4-(3-(4-tolyl)ureido)benzoic, 
4-(3-(4-(trifluromethyl)phenyl)ureido)benzoic, 4-(3-(4-methoxyphenyl)ureido) 
benzoic, 4-(3-(4-fluorophenyl)ureido)benzoic, 4-(3-(4-chlorophenyl)ureido) 
benzoic, 4-(3-(2,4-dichlorophenyl)ureido)benzoic, 4-(3-(4-chloro-
3(trifluoromethyl) phenyl)ureido)benzoic, 3,4,5-OCH3 4-(3-(3,4,5-trimethoxy 
phenyl)ureido)benzoic, 4-(3-cyclohexylureido)benzoic acids (1.4a-1.4k) were 
prepared using the same procedure as above with their  corresponding 
isocyantes.  
 
1.4e Synthesis of methyl 1-(4-(4-(3-phenylureido)benzamido)phenyl)-1H-
indazole-3-carboxylate (1.5a): Synthesis of 1.5a was conducted by taking (PABA 
urea) (10 mmol) and dissolving it in DMF 50mL. triethylamine (30 mmol), EDC 
(11 mmol), and HOBt (11 mmol). Reaction mixture was stirred for 10 min before 
the addition of methyl 1-(4-aminophenyl)-1H-indazole-3-carboxylate (1.4a) (10.5 
mmol). Reaction was warmed to 60 °C and stirred overnight. After completion of 
reaction mixture was poured over ice and filtered. Solid was recrystallized in 




1H NMR (500 MHz, DMSO-d6) δ 10.39 (br. s., 1H), 9.06 (br. s., 1H), 8.81 (br. s., 
1H), 8.23 (d, J = 8 Hz, 1H), 8.08 - 8.11 (m, 2H), 7.99 - 8.02 (m, 2H), 7.90 (d, J = 
8 Hz, 1H), 7.82 (br. s., 2H), 7.61 - 7.67 (m, 3H), 7.50 (d, J = 6 Hz, 3H), 7.33 (d, J 
= 7 Hz, 2H), 7.02 (d, J = 6 Hz, 1H), 3.99 (s, 3H) 
13C NMR (126 MHz, DMSO-d6) δ 165.6, 162.8, 152.8, 143.6, 140.1, 139.9, 139.7, 
136.2, 134.3, 129.4, 129.3, 128.5, 127.9, 124.5, 124.2, 124.1, 122.6, 122.1, 
121.5, 118.9, 117.6, 111.9, 52.4 
HRMS (ESI) m/z: calc’d for C29H23N5O4 [M+H]+ :  506.1823, found 506.1556 
 
1.4f Synthesis of methyl 1-(4-(4-(3-(2-chlorophenyl))benzamido)phenyl)-1H-
indazole-3-carboxylate (1.5b): Synthesis of 1.5b was conducted by taking (paba 
urea) (10 mmol) and dissolving it in DMF 50mL. triethylamine (30 mmol), EDC 
(11 mmol), and HOBt (11 mmol). Reaction mixture was stirred for 10 min before 
the addition of methyl 1-(4-aminophenyl)-1H-indazole-3-carboxylate (1.3) (10.5 
mmol). Reaction was warmed to 60 °C and stirred overnight. After completion of 
reaction mixture was poured over ice and filtered. Solid was recrystallized in 





1H NMR (500 MHz, DMSO-d6) δ 10.41 (s, 1H), 9.77 (s, 1H), 8.44 (s, 1H), 8.19 (d, 
J = 8 Hz, 1H), 8.22 (d, J = 8 Hz, 1H), 8.09 (d, J = 9 Hz, 2H), 8.02 (d, J = 9 Hz, 
2H), 7.88 (d, J = 9 Hz, 1H), 7.80 (d, J = 9 Hz, 2H), 7.56 - 7.72 (m, 3H), 7.44 - 7.53 
(m, 2H), 7.33 (t, J = 8 Hz, 1H), 7.07 (t, J = 8 Hz, 1H), 3.99 (s, 3H) 
13C NMR (126 MHz, DMSO-d6) δ 165.6, 162.8, 152.4, 143.3, 140.1, 139.7, 136.2, 
136.1, 134.3, 129.7, 129.5, 128.4, 128.3, 128.1, 124.4, 124.2, 124.1, 124.1, 
122.7, 122.1, 122.0, 121.5, 117.7, 111.9, 52.4 
HRMS (ESI) m/z: calc’d for C29H22ClN5O4 [M+H]+ :  540.1433, found 540.1127 
1.4g Synthesis of methyl 1-(4-(4-(3-(4-tolyl))benzamido)phenyl)-1H-indazole-3-
carboxylate (1.5c): Synthesis of 1.5c was conducted by taking (paba urea) (10 
mmol) and dissolving it in DMF 50mL. triethylamine (30 mmol), EDC (11 mmol), 
and HOBt (11 mmol). Reaction mixture was stirred for 10 min before the addition 
of methyl 1-(4-aminophenyl)-1H-indazole-3-carboxylate (1.3) (10.5 mmol). 
Reaction was warmed to 60 °C and stirred overnight. After completion of reaction 
mixture was poured over ice and filtered. Solid was recrystallized in acetone to 






1H NMR (500 MHz, DMSO-d6) δ 10.37 (s, 1H), 9.00 (s, 1H), 8.69 (s, 1H), 8.22 (d, 
J = 8 Hz, 1H), 8.08 (d, J = 9 Hz, 2H), 7.98 (d, J = 9 Hz, 2H), 7.88 (d, J = 8 Hz, 
1H), 7.80 (d, J = 9 Hz, 2H), 7.55 - 7.67 (m, 3H), 7.43 - 7.50 (m, 1H), 7.37 (d, J = 
8 Hz, 2H), 7.11 (d, J = 8 Hz, 2H), 3.99 (s, 3H), 2.26 (s, 3H) 
13C NMR (126 MHz, DMSO-d6) δ 165.6, 162.8, 152.8, 143.7, 140.1, 139.7, 137.3, 
136.2, 134.3, 131.5, 129.7, 129.4, 128.5, 127.8, 124.5, 124.2, 124.1, 122.1, 
121.5, 119.0, 117.6, 111.9, 52.4, 20.8 
HRMS (ESI) m/z: calc’d for C30H25N5O4 [M+H]+ :  520.1979, found 520.1707  
1.4h Synthesis of methyl 1-(4-(4-(3-(4-(trifluromethyl))benzamido)phenyl)-1H-
indazole-3-carboxylate (1.5d): Synthesis of 1.5d was conducted by taking (paba 
urea) (10 mmol) and dissolving it in DMF 50mL. triethylamine (30 mmol), EDC 
(11 mmol), and HOBt (11 mmol). Reaction mixture was stirred for 10 min before 
the addition of methyl 1-(4-aminophenyl)-1H-indazole-3-carboxylate (1.3) (10.5 
mmol). Reaction was warmed to 60 °C and stirred overnight. After completion of 
reaction mixture was poured over ice and filtered. Solid was recrystallized in 





1H NMR (500 MHz, DMSO-d6) δ 10.40 (s, 1H), 9.22 (s, 1H), 9.18 (s, 1H), 8.22 (d, 
J = 8 Hz, 1H), 8.08 (d, J = 9 Hz, 2H), 8.00 (d, J = 9 Hz, 2H), 7.88 (d, J = 9 Hz, 
1H), 7.80 (d, J = 9 Hz, 2H), 7.62 - 7.72 (m, 6H), 7.59 (t, J = 7 Hz, 1H), 7.47 (t, J 
= 7 Hz, 1H), 3.99 (s, 3H) 
13C NMR (126 MHz, DMSO-d6) δ 165.6, 162.8, 152.6, 143.7, 143.2, 140.1, 139.7, 
136.2, 134.3, 129.4, 128.5, 128.3, 126.6,126.1,126.1, 124.3 (q), 122.6 (q), 122.1, 
121.5, 118.5, 117.9, 111.9, 52.4 
HRMS (ESI) m/z: calc’d for C30H22F3N5O4 [M+H]+ :  574.1697, found 574.1376 
1.4i Synthesis of methyl 1-(4-(4-(3-(4-methoxyphenyl)benzamido)phenyl)-1H-
indazole-3-carboxylate (1.5e): Synthesis of 1.5e was conducted by taking (PABA 
urea) (10 mmol) and dissolving it in DMF 50mL. triethylamine (30 mmol), EDC 
(11 mmol), and HOBt (11 mmol). Reaction mixture was stirred for 10 min before 
the addition of methyl 1-(4-aminophenyl)-1H-indazole-3-carboxylate (1.3) (10.5 
mmol). Reaction was warmed to 60 °C and stirred overnight. After completion of 
reaction mixture was poured over ice and filtered. Solid was recrystallized in 




1H NMR (500 MHz, DMSO-d6) δ 10.37 (s, 1H), 8.97 (s, 1H), 8.61 (s, 1H), 8.22 (d, 
J = 8 Hz, 1H), 8.08 (d, J = 9 Hz, 2H), 7.98 (d, J = 8 Hz, 2H), 7.88 (d, J = 9 Hz, 
1H), 7.80 (d, J = 9 Hz, 2H), 7.55 - 7.66 (m, 3H), 7.46 (t, J = 8 Hz, 1H), 7.35 - 7.42 
(m, 2H), 6.90 (d, J=8 Hz, 2H), 3.99 (s, 3H), 3.73 (s, 3H) 
13C NMR (126 MHz, DMSO-d6) δ 165.7, 162.8, 155.2, 152.9, 143.8, 140.1, 139.7, 
136.2, 134.3, 132.8, 129.4, 128.4, 127.7, 124.4, 124.2, 124.1, 122.1, 121.5, 
120.7, 117.5, 114.5, 111.9, 55.7, 52.4 
HRMS (ESI) m/z: calc’d for C30H25N5O5 [M+H]+ : 536.1928 , found 536.1628  
1.4j Synthesis of methyl 1-(4-(4-(3-(4-fluorophenyl))benzamido)phenyl)-1H-
indazole-3-carboxylate (1.5f): Synthesis of 1.5f was conducted by taking (PABA 
urea) (10 mmol) and dissolving it in DMF 50mL. triethylamine (30 mmol), EDC 
(11 mmol), and HOBt (11 mmol). Reaction mixture was stirred for 10 min before 
the addition of methyl 1-(4-aminophenyl)-1H-indazole-3-carboxylate (1.3) (10.5 
mmol). Reaction was warmed to 60 °C and stirred overnight. After completion of 
reaction mixture was poured over ice and filtered. Solid was recrystallized in 




1H NMR (500 MHz, DMSO-d6) δ 10.38 (s, 1H), 9.05 (s, 1H), 8.83 (s, 1H), 8.22 (d, 
J = 8 Hz, 1H), 8.07 (d, J = 9 Hz, 2H), 7.98 (d, J = 9 Hz, 2H), 7.88 (d, J = 9 Hz, 
1H), 7.80 (d, J = 9 Hz, 2H), 7.55 - 7.67 (m, 3H), 7.40 - 7.53 (m, 3H), 7.09 - 7.21 
(m, 2H), 3.99 (s, 3H) 
13C NMR (126 MHz, DMSO-d6) δ 165.6, 162.8,158.9, 157.0, 152.9, 143.6, 140.1, 
139.7, 136.2, 134.3, 129.4, 128.5, 127.9, 124.5, 124.2, 124.1, 122.1, 121.5, 
120.7, 120.7, 117.7, 115.9, 115.7, 111.9, 52.4 
HRMS (ESI) m/z: calc’d for C29H22FN5O4 [M+H]+ :  524.1729, found 524.1447  
1.4k Synthesis of methyl 1-(4-(4-(3-(4-chlorophenyl))benzamido)phenyl)-1H-
indazole-3-carboxylate (1.5g): Synthesis of 1.5g was conducted by taking (PABA 
urea) (10 mmol) and dissolving it in DMF 50mL. triethylamine (30 mmol), EDC 
(11 mmol), and HOBt (11 mmol). Reaction mixture was stirred for 10 min before 
the addition of methyl 1-(4-aminophenyl)-1H-indazole-3-carboxylate (1.3) (10.5 
mmol). Reaction was warmed to 60 °C and stirred overnight. After completion of 
reaction mixture was poured over ice and filtered. Solid was recrystallized in 





1H NMR (500 MHz, DMSO-d6) δ 10.38 (s, 1H), 9.08 (s, 1H), 8.94 (s, 1H), 8.21 (d, 
J = 8 Hz, 1H), 8.08 (d, J = 9 Hz, 2H), 7.99 (d, J = 8 Hz, 2H), 7.87 (d, J = 8 Hz, 
1H), 7.79 (d, J = 9 Hz, 2H), 7.63 (d, J = 9 Hz, 2H), 7.59 (t, J = 8 Hz, 1H), 7.49 - 
7.55 (m, 2H), 7.42 - 7.48 (m, 1H), 7.35 (d, J = 9 Hz, 2H), 3.98 (s, 3H) 
13C NMR (126 MHz, DMSO-d6) δ 165.6, 162.8, 152.7, 143.4, 140.1, 139.7, 138.9, 
136.2, 134.3, 129.4, 129.1, 128.4, 128.1, 126.1, 124.4, 124.2, 124.1, 122.1, 
121.5, 120.4, 117.8, 111.9, 52.4 
HRMS (ESI) m/z: calc’d for C29H22ClN5O4 [M+H]+ :  540.1433, found 540.1137 
1.4l Synthesis of methyl 1-(4-(4-(3-(2,4-dichlorophenyl))benzamido)phenyl)-1H-
indazole-3-carboxylate (1.5i): Synthesis of 1.5i was conducted by taking (PABA 
urea) (10 mmol) and dissolving it in DMF 50mL. triethylamine (30 mmol), EDC 
(11 mmol), and HOBt (11 mmol). Reaction mixture was stirred for 10 min before 
the addition of methyl 1-(4-aminophenyl)-1H-indazole-3-carboxylate (1.3) (10.5 
mmol). Reaction was warmed to 60 °C and stirred overnight. After completion of 
reaction mixture was poured over ice and filtered. Solid was recrystallized in 




1H NMR (500 MHz, DMSO-d6) δ 10.40 (s, 1H), 9.85 (s, 1H), 8.57 (s, 1H), 8.18 - 
8.24 (m, 2H), 8.05 - 8.11 (m, 2H), 8.01 (d, J = 9 Hz, 2H), 7.88 (d, J = 9 Hz, 1H), 
7.77 - 7.82 (m, 2H), 7.61 - 7.67 (m, 3H), 7.55 - 7.61 (m, 1H), 7.44 - 7.49 (m, 1H), 
7.41 (d, J = 9 Hz, 1H), 3.98 (s, 3H) 
13C NMR (126 MHz, DMSO-d6) δ 165.6, 162.8, 152.3, 143.1, 140.1, 139.7, 136.2, 
135.4, 134.3, 129.5, 129.1, 128.5, 128.4, 128.2, 126.9, 124.5, 124.2, 124.1, 
123.4, 122.8, 122.1, 121.5, 117.8, 111.9, 52.4 
HRMS (ESI) m/z: calc’d for C29H21 Cl2N5O4 [M+H]+ :  574.1043 , found 574.0724 
1.4m Synthesis of methyl 1-(4-(4-(3-phenylureido)benzamido)phenyl)-1H-
indazole-3-carboxylate (1.5i) Synthesis of 1.5i was conducted by taking (PABA 
urea) (10 mmol) and dissolving it in DMF 50mL. triethylamine (30 mmol), EDC 
(11 mmol), and HOBt (11 mmol). Reaction mixture was stirred for 10 min before 
the addition of methyl 1-(4-aminophenyl)-1H-indazole-3-carboxylate (1.3) (10.5 
mmol). Reaction was warmed to 60 °C and stirred overnight. After completion of 
reaction mixture was poured over ice and filtered. Solid was recrystallized in 




1H NMR (500 MHz, DMSO-d6) δ 10.40 (s, 1H), 9.28 (s, 1H), 9.22 (s, 1H), 8.18 - 
8.24 (m, 1H), 8.14 (s, 1H), 8.08 (d, J = 8 Hz, 2H), 8.00 (d, J = 8 Hz, 2H), 7.88 (d, 
J = 8 Hz, 1H), 7.80 (d, J = 8 Hz, 2H), 7.54 - 7.71 (m, 5H), 7.46 (t, J = 8 Hz, 1H), 
3.98 (s, 3H) 
13C NMR (126 MHz, DMSO-d6) δ 165.6, 162.8, 152.7, 143.1, 140.1, 139.7, 139.5, 
136.2, 134.3, 132.5, 129.4, 128.5-127.1(q), 124.4 (q), 124.2, 124.1, 123.7, 123.1, 
122.2, 122.1, 121.5, 120.0, 118.1, 117.4, 117.4, 111.9, 52.4 
 
1.4n Synthesis of methyl 1-(4-(4-(3-(4-chloro-3-(trimethoxy)phenyl) benzamido) 
phenyl)-1H-indazole-3-carboxylate (1.5j):  Synthesis of 1.5j was conducted by 
taking (PABA urea) (10 mmol) and dissolving it in DMF 50mL. triethylamine (30 
mmol), EDC (11 mmol), and HOBt (11 mmol). Reaction mixture was stirred for 10 
min before the addition of methyl 1-(4-aminophenyl)-1H-indazole-3-carboxylate 
(1.3) (10.5 mmol). Reaction was warmed to 60 °C and stirred overnight. After 
completion of reaction mixture was poured over ice and filtered. Solid was 




1H NMR (500 MHz, DMSO-d6) δ 10.37 (s, 1H), 8.99 (s, 1H), 8.74 (s, 1H), 8.22 (d, 
J = 8 Hz, 1H), 8.07 (d, J = 9 Hz, 2H), 7.98 (d, J = 9 Hz, 2H), 7.88 (d, J = 8 Hz, 
1H), 7.80 (d, J = 9 Hz, 2H), 7.55 - 7.66 (m, 3H), 7.40 - 7.51 (m, 1H), 6.82 (s, 2H), 
3.97 (s, 3H), 3.76 (s, 6H), 3.61 (s, 3H) 
13C NMR (126 MHz, DMSO-d6) δ 165.6, 162.8, 153.4, 152.7, 143.5, 140.1, 139.7, 
136.2, 136.0, 134.3, 133.2, 129.4, 128.4, 127.9, 124.4, 124.2, 124.1, 122.1, 
121.5, 117.7, 111.9, 96.7, 60.6, 56.2, 52.4 
HRMS (ESI) m/z: calc’d for C32H29N5O7 [M+H]+ : 596.2140 , found 596.1865 
1.4o Synthesis of methyl 1-(4-(4-(3-cyclohexylureido))benzamido)phenyl)-1H-
indazole-3-carboxylate (1.5k): Synthesis of 1.5k was conducted by taking (PABA 
urea) (10 mmol) and dissolving it in DMF 50mL. triethylamine (30 mmol), EDC 
(11 mmol), and HOBt (11 mmol). Reaction mixture was stirred for 10 min before 
the addition of methyl 1-(4-aminophenyl)-1H-indazole-3-carboxylate (1.3) (10.5 
mmol). Reaction was warmed to 60 °C and stirred overnight. After completion of 
reaction mixture was poured over ice and filtered. Solid was recrystallized in 





1H NMR (500 MHz, DMSO-d6) δ 10.32 (s, 1H), 8.68 (s, 1H), 8.21 (d, J = 8 Hz, 
1H), 8.07 (d, J = 9 Hz, 2H), 7.93 (d, J = 9 Hz, 2H), 7.87 (d, J = 8 Hz, 1H), 7.78 (d, 
J = 9 Hz, 2H), 7.50 - 7.61 (m, 3H), 7.37 - 7.48 (m, 1H), 6.23 (d, J = 8 Hz, 1H), 
3.98 (s, 3H), 3.43 - 3.55 (m, 1H), 2.08 (s, 1H), 1.77 - 1.86 (m, 2H), 1.68-1.50 (m, 
3H), 1.25 - 1.38 (m, 2H), 1.13 - 1.24 (m, 3H) 
13C NMR (126 MHz, DMSO-d6) δ 165.7, 162.8, 154.5, 144.4, 140.1, 139.8, 136.1, 
134.2, 129.3, 128.4, 127.0, 124.4, 124.2, 124.1, 122.1, 121.4, 116.9, 111.9, 52.4, 
48.2, 33.3, 25.7, 24.8 
HRMS (ESI) m/z: calc’d for C29H29N5O4 [M+H]+ :  512.2292, found 512.2034 
1.4p Synthesis of 1-(4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)benz 
amido)phenyl)-1H-indazole-3-carboxylic acid (1.6i): Synthesis of 1.6i was 
conducted by taking (1.5i) (5 mmol) and dissolving it in DMSO 30mL. 2.5 M NaOH 
(5mL) was added and the reaction mixture was heated. Upon completion of 
hydrolysis reaction mixture was poured over ice and acidified with 3 M HCl 






1.4q Synthesis of 1-(4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido) 
benzamido)phenyl)-N-(2-(dimethylamino) ethyl)-1H-indazole-3-carboxamide 
(1.7i): Synthesis of 1.7i was conducted by taking 1.6i (2 mmol) and dissolving it 
in DMF 10mL. Triethylamine (2.2 mmol), EDC (2.2 mmol), and HOBt (2.2 mmol) 
was added to the solution. The reaction mixture was stirred for 10 min before the 
addition of N,N′-Dimethylethylenediamine (2.5 mmol). Reaction was warmed to 
60 °C and stirred overnight. After completion of reaction, the mixture was poured 
over ice and filtered. Resulting solid was recrystallized in ethyl acetate. 
 
1H NMR (500 MHz, DMSO-d6) δ 10.37 (s, 1H), 9.39 (s, 1H), 9.31 (s, 1H), 8.36 
(t, J = 6 Hz, 1H), 8.30 (d, J = 8 Hz, 1H), 8.13 (s, 1H), 8.05 (d, J = 8 Hz, 2H), 7.99 
(d, J = 8 Hz, 2H), 7.77 - 7.84 (m, 4H), 7.60 - 7.69 (m, 4H), 7.54 (t, J = 8 Hz, 1H), 
7.37 (t, J = 8 Hz, 1H), 3.41 - 3.47 (m, 2H), 2.45 - 2.51 (m, 2H), 2.21 (s, 6H) 
56 
 
13C NMR (126 MHz, DMSO-d6) δ 165.5, 162.1, 152.7, 143.1, 140.1, 139.6, 139.4, 
139.3, 134.6, 132.5, 129.3, 128.4, 128.3, 124.0, 123.7(q), 123.6, 123.5, 123.0(q), 
122.7, 121.4, 118.0, 117.4, 117.4, 111.4, 58.5, 45.5, 36.9 
HRMS (ESI) m/z: calc’d for C33H29ClF3N7O3 [M+H]+ :  664.2045, found 664.1690 
1.4r 4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-N-(4-(3-(4-methyl 
piperazine-1-carbonyl)-1H-indazol-1-yl)phenyl)benzamide (1.8i): Synthesis of 
1.8i was conducted by taking (1.6i) (2 mmol) and dissolving it in DMF 10mL. 
Triethylamine (2.2 mmol), EDC (2.2 mmol), and HOBt (2.2 mmol) was added to 
the solution. The reaction mixture was stirred for 10 min before the addition of N 
methyl piperazine (2.5 mmol). Reaction was warmed to 60 °C and stirred 
overnight. After completion of reaction, the mixture was poured over ice and 
filtered. Resulting solid was recrystallized in ethyl acetate. 
 
1H NMR (500 MHz, DMSO-d6) δ 10.37 (s, 1H), 9.32 (s, 1H), 9.26 (s, 1H), 8.14 (d, 
J = 1.95 Hz, 1H), 8.02 - 8.09 (m, 3H), 8.02 - 8.03 (m, 1H), 7.99 (d, J = 8.79 Hz, 
2H), 7.85 (d, J = 8.30 Hz, 1H), 7.78 (d, J = 8.79 Hz, 2H), 7.61 - 7.71 (m, 5H), 7.55 
(t, J = 7.56 Hz, 1H), 7.32 - 7.40 (m, 1H), 3.97 (br. s., 2H), 3.76 (br. s., 2H), 3.34 
(br. s., 1H), 2.33 - 2.46 (m, 4H), 2.22 (s, 3H) 
57 
 
13C NMR (126 MHz, DMSO-d6) δ 165.6, 161.8, 152.7, 143.1, 140.1, 139.6, 139.3 
139.1, 134.7, 132.5, 129.3, 128.5, 128.4,127.3(q), 127.1, 123.8, 123.3, 122.4, 
122.2, 121.6, 118.1, 117.4, 111.3, 55.7, 54.9, 47.0, 46.1, 42.3, 31.2  
HRMS (ESI) m/z: calc’d for C34H29ClF3N7O3 [M+H]+ :  676.2045, found 676.1673 
 
1.4s Cell lines and culture conditions 
4T1 cells were purchased from Caliper Life Sciences and were cultured in 
RPMI-1650 supplemented with FBS (10%) and penicillin-streptomycin (50 U/mL, 
50 µg/mL). 
GL261-luc2 cells were purchased from Perkin-Elmer and cultured in 
DMEM supplemented with geneticin G418 (50 µg/mL), FBS (10%) and penicillin-
streptomycin (50 U/mL, 50 µg/mL). 
MDA-MB-231 cells were purchased from ATCC and were cultured in 
DMEM supplemented with FBS (10%, Atlanta Biologicals) and penicillin-
streptomycin (50 U/mL, 50 µg/mL, Invitrogen).  
MIAPaCa-2 cells were purchased from ATCC and were cultured in DMEM 
supplemented with FBS (10%, Atlanta Biologicals), Horse serum (1% Atlanta 
Biologicals), and penicillin-streptomycin (50 U/mL, 50 µg/mL, Invitrogen).  
WiDr cells were purchased from ATCC and were cultured in MEM 
supplemented with FBS (10%) and penicillin-streptomycin (50 U/mL, 50 µg/mL).  
HUVEC cells were purchased from ATCC and were cultured in F-12K 





1.4t MTT assay 
Cells (5 x 103 cells/well) were cultured in 96-well plates and incubated for 
18-24 hours. Stock solution of compound was made up at 100 mM concentration 
in DMSO. The final concentration of DMSO in the wells were < 0.01%. 
Concentration range of compounds from 100 µM to 0.1 µM was tested by adding 
2x concentration of test compound to the first well and then the serial dilutions by 
going from well to well. All the compounds were tested in duplicates. After 72 
hours of treatment, 10 µL of MTT (5 mM in 1x PBS) was added into the wells and 
the cells were incubated for a period of 4 hours. At this point, the conversion of 
MTT to formazan was quenched by the addition of 100 µL of SDS (1 g of SDS 
dissolved in 0.01 N HCl) and the cells were incubated for further 4 hours. The 
absorbance was recorded at 570 nm using BioTek Synergy 2 plate reader. The 
absorbance is directly proportional to the cell viability. % Survival was calculated 
using the formula  
% survival = (absorbance of test compound/absorbance of control) x 100%. 
IC50 was calculated using GraphPad Prism software, by plotting a dose-
response curve with log[concentration] on x-axis and % survival on y-axis and 
analyzing via nonlinear regression with variable slope. 
1.4u Endothelial Cell Tube Formation Assay  
Culture plates were coated with Corning Matrigel Matrix (10mg/mL). 
HUVEC cells were plated at 4 x 105 cell/mL with 300 μL/well. Compound 1.5i and 
1.8i were added to wells each at concentrations of 1 μM and 5 μM. Cells were 
then allowed to incubate for a period of 18-24 hours. Media was then gently 
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aspirated as to not disrupt the formation of tubes and then washed with 750 μL 
of HBSS 2x. Cells were labeled by adding 300 μL/well of 8 μg/mL Corning Calcein 
AM in HBSS and incubate plates for 30 to 40 minutes at 37°C, 5% CO2. Once 
again cells were washed with HBSS. Cells were then imaged on a fluorescence 
microscope and tube length was measured.  
1.4v Ethical Considerations for animal studies 
The experimental procedures involving animals that were conducted at the 
University of Minnesota Duluth were in compliance with the U.S. National 
Institutes of Health Guide for Care and Use of Laboratory Animals and approved 
by the Institutional Animal Care and Use Committee at the University of 
Minnesota (UMN).  
1.4w General procedure for systemic toxicity evaluation 
 Mice were procured from Charles River, and acclimatized at room 
temperature for a period of 7 days. The mice were weighed and randomized into 
groups (n = 6 mice per group) based on same average weights. Mice were 
housed as two mice per cage. Treatment was started via i.p. and body weights 
were monitored for a period of 14-21 days. At the end of the study, mice were 
euthanized using CO2.  
1.4x Anticancer efficacy of compound 1.5i, 1.7i, and 1.8i in WiDr flank model 
5 x 106 WiDr cells were suspended in a mixture of 1:1 matrigel-PBS 
(100µL). These cells were then injected subcutaneously onto the right flank of 
aythamic nude mice and tumors were measured via calipers and the tumor 
volume was calculated using the formula 
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𝑉 =  
1
2
× 𝑎 × 𝑏2  
where ‘a’ is the long diameter of the tumor and ‘b’ is the short diameter of the 
tumor.  Mice were assigned into groups (n = 8 mice per group) when the average 
tumor volume reached ~100-200 mm3 and the treatment was initiated and 
continued for a period of 21 days. Tumor volume was recorded every 2-3 days 
and at the end of the study, mice were euthanized, and tumors were resected 





× 100  
where C is average tumor weight of the control group and T is the average tumor 
weight of the test group.  
 
1.4y Anticancer efficacy of compound 1.8i in 4T1 flank model: 
5 x 104 4T1 cells were suspended in a mixture of 1:1 matrigel-PBS (100µL). 
These cells were then injected subcutaneously onto the right flank of Balb/C mice 
and tumors were measured via calipers. Volumes and measurements were 





























































































































Chapter 2: Synthesis and Evaluation of Piperazinyl Curcuminoid Based 
Quaternary Salts as Anticancer Agents 
2.1 Introduction  
2.1a Natural products as medicinal agents 
Evolution has allowed nature to design an infinite number of organic compounds 
that can be studied and used for medicinal purposes. In nature, species were 
driven to evolve for survival that results in highly specialized compounds for 
signaling, protection, and mating. Such compounds found in nature have been 
repurposed extensively as medicinal agents in the past few decades.75 Natural 
products are chemicals produced by living organisms and can be found in nature. 
The repurposing includes the use of natural products as antibiotics, antiparasitics, 
anti-cancer, analgesics, and anesthesia.76–78 Flavonoids are a sub group of 
natural products that are polyphenolic compounds and can readily be found in 
fruits, vegetables, wine, and tea. Flavonoids are readily extracted from common 
foods such as peanuts, dark chocolate, green tea and turmeric.76–78 Flavonoids 
have been given high interest due to their supposed protective role in cancer 
prevention which includes pro-oxidant activity, mitochondrial toxicity, and 
interactions with drug-metabolizing enzymes.77,79 
2.1b Turmeric and its anticancer agent curcumin 
Curcumin has been one of the most studied natural products. Curcumin is the 
yellow spice derived from the roots, rhizome, of the plant Curcuma longa.77 The 
roots are commonly known as turmeric which has been widely used in Asia for 
thousands of years in food as a preservative, a coloring agent, and has also been 
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used as medicine for treating wide variety of diseases.76–78 Extracts of turmeric 
contain flavonoid mimicking three curcuminoids are namely curcumin, 
demethoxycurcumin, and bisdemethoxycurcumin. Curcuminoids are often 
extracted with ethanol and can range from 2-8% of the total composition.76 
2.1c Chemical properties of curcumin 
The molecular formula of curcumin was first reported in the early 19th century by 
Vogel and Pellatie and nearly a century later was identified by Lampe and 
Milobedzka. Curcumin is a crystalline solid that does not dissolve in water but 
can be solubilized in many organic solvents. Curcumin has high absorbance and 
fluoresces under the right conditions. Maximum absorbance is between 425 and 
430 nm in methanol. In aqueous mediums curcumin does not have fluorescence, 
however, upon conjugation with ions, lipids, and proteins it can exhibit high 
fluorescence. This unique property is extremely helpful in visualizing the 
localization and uptake of curcumin in cells.77 
Curcumin is a bis α,β-unsaturated β-ketone that can exist as either bis keto or 
keto enol forms (Figure 2.1). In acidic or neutral conditions, the bis keto 
dominates and under basic conditions, the enolate form is more prevalent. As a 
result, it is a potent proton donor from pH 3-7 and at pH > 8, it acts as an electron 
donor.75 
 





2.1d Curcumin as a therapeutic agent  
Curcumin has been reported as a promising natural product in the treatment of 
wide variety of diseases due to its pleotropic effects with no reported side effects 
even at high concentrations.80 Curcumin has been traditionally used in prevention 
and treatment of several conditions and diseases. Curcumin has been shown to 
have hepato- and nephro-protective, thrombosis suppressing, myocardial 
infarction-protective properties.81 Other properties that make curcumin the most 
interesting natural product is due to its strong antioxidant, antimicrobial, 
anticarcinogenic and anti-inflammatory properties (Figure 2.2).77,82–84 
96 
 
Figure 2.2 Therapeutic properties of curcumin 
Curcumin has shown suppression of nuclear transcription factor NF–κB, down 
regulation of cyclooxygenase-2 (cox2), decrease in cellular nitric oxide (NO), 
decrease in cell surface adhesion molecules, and decrease in inflammatory 
cytokines IL-1-8.77,85,86 NF–κB is an inducible transcription factor that regulates 
genes expression involved in inflammation, cell proliferation and cell survival. 
75,78,82,83,87 Cox-2 is responsible for the formation of prostanoids including 
thromboxane and prostaglandins such as prostacyclin. Cox is often 
overexpressed in cancer and have multifaceted roles in carcinogenesis, 



















many roles in pathogenesis of cancer. NO has been suggested to modulate 
different cancer-related events including angiogenesis, apoptosis, cell cycle, 
invasion, and metastasis.77,89 Cytokines are often released in response to cellular 
stress that include infection, inflammation, and carcinogenesis.77,86 
Carcinogenesis results in stress due to the need of additional nutrients and 
building blocks for continued proliferation. Cancer-associated cytokines have 
numerous different roles including promotion of angiogenesis, immunoprotection, 
increased invasiveness, motility, and metastasis.1,85 Together, these effects of 








Figure 2.3: Multiple modes of biological activity of curcumin 
Owning to all the biological properties of curcumin in in vitro, there has been a 
large interest in understanding the pharmaceutical properties of curcumin. In this 
regard, numerous pharmacokinetic studies have been performed and revealed 
that curcumin undergoes rapid and extensive metabolism. Bioavailability of 
curcumin is extremely limited due to metabolic instability, poor water solubility, 
and rapid elimination.90–92 Curcumin is highly susceptible to glucuronidation and 
sulfation of the phenols making it a readily excretable compound (Figure 2.4). As 
a result, clinical studies with curcumin have been conducted at very high doses 
of up to 12 grams daily.90,93 While these high does did not show toxic effects, mild 
99 
 
side effects such as diarrhea and nausea were observed.90,93 However it is highly 
impractical and medically not recommended to administer 12 grams of 
therapeutic in either acute or chronic setting. Efforts to increase the bioavailability 
include nanoformulations, and formulations with phosphotidylcholine.86,94 
 
Figure 2.4: Metabolites of curcumin 
 
Numerous modification sites are present in the in curcumin that have been 
modified to increase the anti-inflammatory, antioxidant, antimalarial, and 
anticarcinogenic effects, increase solubility, and improve pharmacological 
properties (Figure 2.5). However, the existing modifications have been met with 
little clinical success and as a result further development is needed. Some of the 
modification on curcumin template to improve its potency by extensive 






Figure 2.5 Modification sites of curcumin, red circle highlights aromatic 
substitution, blue α, β unsaturation, green diketo and yellow denotes carbonyl 
 
Zhou et al. synthesized a series of curcuminoid compounds containing 
benzyl piperidone (Scheme 2.1). They evaluated the ability of the synthesized 
compounds to inhibit proliferation on human prostate cancer PC-3, pancreas 
cancer BxPC-3, colon cancer HT-29 and lung cancer cells H1299. Compounds 
showed increased activity compared to native curcumin. In fact, the lead 
compound was found to be ~40 times more potent than curcumin on all the tested 
cell lines. Toxicity of the remaining compounds showed IC50 values ranging from 
0.41 to 17.67 µM.95 
 
Scheme 2.1: Synthesis of piperidone curcuminoids as anticancer agents 
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Ferrari et al. synthesized a series of ester and carboxylic acid modified 
curcuminoids in an attempt to improve chemical stability and anti-cancer activity 
(Figure 2.6).  Compounds were evaluated for activity against different 
tumorigenic cell lines human ovarian carcinoma cells, A2780, and A2780/CP, and 
human colon carcinoma cells HCT116 and LoVo. Results showed improved 
toxicity of compared to curcumin, with the esters being more active than acids.96 
 
Figure 2.6: Synthesis of carboxylic and ester based curcuminoids 
Ahsan et al. synthesized a novel class of heterocyclic azole-based 
curcumin analogs (Scheme 2.2). Compounds were synthesized to yield three 
different types, pyrazole amide, pyrazole urea, and pyrimidinone. Compounds 
were tested against a NCI 60 cell line panel at five doses. Many of the compounds 
exhibited greater activity compared to curcumin with toxicity in low micro 
concentrations. Pyrazole based curcuminoids are being further developed as 





Scheme 2.2: Synthesis of azole based curcuminoids 
Shim et al. reported the synthesis of a class of semisynthetic 
hydrazinocurcuminoids. The lead compound (Figure 2.7) was found to inhibit 
bovine aortic endothelial cells (BAECs) at a nanomolar concentration.98 
 
Figure 2.7: Structure of hydrazinocurcuminoid 
Ishida et al. reported the synthesis of several curcuminoids with substitutions on 
the central carbon. Furthermore, they evaluated the in vitro cytotoxicity on a panel 
of human cancer cell lines. The most potent compound was shown in Figure 2.8. 
This compound showed proliferation inhibition across multiple cell lines including 
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HOS, bone ostesarcoma 1A9, breast cancer with IC50 values in low micromolar 
range. 99 
 
Figure 2.8: Structure of lead candidate compound with substitution on central 
carbon 
Adams et al. synthesized a series of novel curcuminoids with modified diketo 
component. Modifications included mono ketone, cyclic ketone, and reduced 
monoketone (Figure 2.9). Compounds were evaluated for anticancer and 
antiangiogenic activities. Screening showed that the curcuminoids containing the 
cyclic ketone had increased in vitro anticancer and antiangiogenetic activity 
compared with the diketone structure of curcumin.95 
 
Figure 2.9: structure of modified mono ketones and alcohols of curcuminoid 
origin 
 
2.1e Curcumin formulations 
As mentioned above, curcumin is a natural product with a diverse set of medicinal 
properties. The metabolic lability of curcumin has led to an effort to formulate 
curcumin to increase clinical potential. Formulations of curcumin focus on 
improving the bioavailability and currently, there are several well studied 
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formulations. It has been found that NovaSol®, CurcuWin®, and LongVida® 
exhibited over 100-fold higher bioavailability relative to reference unformulated 
curcumin. As a result, these are the leading formulations of curcumin being 
developed further.  
CurcuWin® is currently being developed by OmniActive Health 
Technologies.  CurcuWin® is a novel formulation of curcumin comprised of 20%–
28% turmeric powder, 63%–75% polyvinyl pyrrolidine, 10%–40% cellulosic 
derivatives and 1–3% natural antioxidants that allows for increased water 
solubility and bioavailability. Studies found the relative bioavailability was 130-
140 times higher than unformulated curcumin.100 
NovaSol® is a liquid micelle formulation of curcumin being developed by 
Frutarom. NovaSol® curcumin micelles were formulated of 7% curcumin powder 
(6% curcumin) and 93% Tween-80. This micellation of curcumin showed ~185 
times the relative bioavailability compared to native curcumin.101 
LongVida® is currently being developed by Verdure Sciences. LongVida® 
is a solid lipid curcumin particle based formulation. Advantages of this formulation 
prevents curcumin from rapid degradation and excretion resulting in an increased 
half-life. LongVida® currently is comprised between 20% and 30%, however 
further modifications are in the works adjusting the composition percentages. 
LongVida® also contains soy lecithin containing purified phospholipids, 
docosahexaenoic acid, stearic acid and ascorbic acid.102 
2.1f Baylis-Hillman reaction 
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 One of the robust reaction that we intended to utilize for the synthesis of 
novel curcuminoid based derivatives is Baylis-Hillman reaction. Baylis-Hillman 
reactions are highly atom efficient and have little to no waste or byproducts 
generated.103–105 Another interesting feature is that this reaction is solvent free 
thus making it environmentally benign. Baylis-Hillman reaction involves 
condensation of aldehydes and electron deficient ketones with different 
unsaturated systems to produce functionalized allylic alcohols (Scheme 2.3). 
 
Scheme 2.3: Baylis-Hillman reaction. 
These alcohols can be readily converted to leaving groups such as acetates and 
bromides with acetic anhydride and HBr/H2SO4 respectively (Scheme 2.4).  
 
Scheme 2.4: Conversion of Baylis-Hillman alcohols to acetates and bromides 
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The acetates of product BH alcohols can be isomerized with various 
nucleophiles in SN2’ fashion to provide further functionalized structural synthons 
(Scheme 2.5).  
 
Scheme 2.5: SN2’ capability of BH acetates. 
The BH alcohols can also be converted into allyl bromides by reacting 
them with HBr/H2SO4 or PBr3 (Scheme 2.4). The bromides have increased 
versatility where nucleophilic substitutions can occur in three different ways, SN2, 
allylic rearrangement in SN2’ mode, and 1,4-addition reaction (Figure 2.10). 
 
 
Figure 2.10: SN2, SN2’, and 1,4 addition capabilities of Baylis-Hillman bromides. 
Below are some of the literature methods where Baylis-Hillman reaction 
was utilized in synthesizing biologically relevant molecules. 
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Klossowski et al. reported the synthesis of novel peptidomimetic inhibitors 
of thioredoxin−thioredoxin reductase system via O-alkylation of substituted 
cesium benzoates with α-methylbromo acrylamides derivatives to provide target 
compound in Scheme 2.6. In vitro cell proliferation inhibition showed IC50 values 
between 3.4-25µM for many of the derivatives on numerous cell lines. 
Furthermore, in vivo evaluation of these derivatives showed significant tumor 
growth reduction against EMT6, breast cancer cells.106 
 
 
Scheme 2.6: Synthesis of BH bromide derived peptidomimetics. 
 
 Baylis Hillman bromides were utilized in the synthesis of 3-benzylidene-
pyrrolidine-2,5-dione via nucleophilic displacement of bromide with sodium 
cyanide in SN2 fashion. After substitution, nitriles were concerted to amides and 
subsequent cyclization under basic conditions to obtain 3-benzylidene-




Scheme 2.7: Synthesis of 3-benzylidene-pyrrolidine-2,5-dione using BH bromide  
 
Spyvee, M., et al. further developed of 3-benzylidene-pyrrolidine-2,5-
diones into a class of selective notch inhibitors. Compounds were evaluated for 
anticancer activity on numerous cell lines both notch dependent and 
independent. Results showed activity selectively towards notch dependent cell 
lines. Furthermore, compound 1-134-83 (Figure 2.11) was evaluated in vivo 
against esophageal adenocarcinoma, OE19, and showed significant tumor 
reduction at dosages of 15mg/Kg.108 
 
Figure 2.11: structure of 1-134-83 
Nelson et al. synthesized Baylis-Hilman substituted imidazoles and 
triazoles for their antifungal activity against C. neoformans (Scheme 2.8).   
Several halogenated aromatic imidazole and triazole derivatives exhibited 
promising anti-fungal activity against C. neoformans (~8-13 µg/mL). The active 
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molecules exhibited little to no cytotoxicity when tested on proliferating breast 
cancer cell line MCF-7 (up to 50µM).109 
 
Scheme 2.8: Synthesis of Baylis-Hilman substituted imidazoles and triazoles 
Extending the chemical applications of Baylis Hillman, Mereddy et al. 
carried out Zn based Barbier allylations on o-formyl phenyl boronic acids to 
synthesize functionalized benzoxaboroles as potential antimicrobial and 
antifungal agents.110 The reaction took place in a highly diasteroselective (syn) 
manner with BH bromide to obtain diastereometrically pure compound (Scheme 
2.9). Activity of the synthesized compounds was limited on gram positive 
Streptococcus thermophilus and gram negative Pseudomonas aeruginosa 





Scheme 2.9: Synthesis of functionalized benzoxaboroles from BH bromides. 
Ronayne et al. previously synthesized a library of compounds with the Baylis-
Hillman template as potential DNA alkylators. The reported synthesis produces 
benzoates, naphthoates, and nicotinates from the corresponding carboxylic acids 
and Baylis-Hilman bromides. The Compound shown was chosen as the lead 
(Scheme 2.9). It exhibited good activity on multiple cell lines including MDA-MB-
231 (4µM), 4T1 (6µM), and MIAPaCa-2 (3µM). Furthermore, this compound 
demonstrated an ability to bind to cellular nucleophiles due to increased nuclear 
disorganization and DNA damage. In vitro results were then translated to in vivo 
systems where this compound showed statistically significant tumor reduction in 
triple negative breast cancer (TNBC) MDA-MB-231 xenograft model at a dose of 
20mg/Kg.111 
Scheme 2.9: Synthetic schemes for biologically active Baylis Hillman derived 
symmetrical curcumin-like template 
 
2.1g Quaternary ammonium salts 
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To improve the water solubility, we intended to introduce quaternary 
ammonium salts in the curcuminoid template. Quaternary ammonium salts are 
an important class of compounds with unique chemical and biological properties. 
Quaternary ammonium salts are a group of organic compounds that contain a 
positively charged nitrogen atom on lipophilic backbones.112–114 Chemically, 
quaternary ammonium compounds are soluble in both aqueous as well as 
organic mediums, allowing for their use as phase transfer catalysts.112–114 Tuning 
of the solubility is easily obtainable through modification of carbon chain length. 
Commercially, these compounds are produced as surfactants, cleaners, and 
fabric softeners.112–114 Biologically, the polar ammonium component and the 
nonpolar chain group allows them to interact with cellular membranes.112–114 
Medicinally, quaternary ammonium compounds have been used as 
antibacterials, antivirals, anticancer, muscle relaxants and spermicides. High 
throughput screening of quaternary ammonium salts showed that over 60% show 
disruption of mitochondrial activity with a majority illustrating disruption of 
complex 1.112–114 
A small literature review on various quaternary ammonium salts and their 
biological relevance are presented below. 
Benzalkonium chloride is a quaternary ammonium salt that functions as 
a cationic surfactant (Figure 2.12).115 Utility of benzalkonium chloride varies but 
has three primary uses as a biocide, a cationic surfactant, and as a phase 
transfer agent. As a biocide benzalkonium chlorides primarily cause dissociation 
of cellular membrane lipid bilayers.115 They also play a role in disruption of 
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respiratory and metabolic activities. As a result, benzalkonium chlorides have 
been investigated for use in hand sanitizers.115 
 
 
Figure 2.12: Structural template for various alky chain containing benzalkonium 
chlorides 
Cetyl-pyridinium chloride (Figure 2.13) is a cationic quaternary 
ammonium compound used in some types of mouthwashes, toothpastes, 
lozenges, throat sprays, breath sprays, and nasal sprays. It is an antiseptic that 
kills bacteria and other microorganisms.115 It has been shown to be effective in 
preventing dental plaque and reducing gingivitis. It has also been used as an 
ingredient in certain pesticides.115 Recently, it has been investigated as a 
potential mitochondrial disrupting agent for the use of cancer.115 
 
Figure 2.13: Structure of Cetylpyridinium chloride 
ESC8 is a quaternary ammonium salt derivative of estrogen (Figure 2.14). 
First synthesized by Sinha et al., it has been shown to induce apoptosis in cancer 
cells through mitochondrial damage.  The modification of including the 
ammonium salt has increased toxicity to hormone negative breast cancers while 
113 
 
keeping selective toxicity to cancer cells.116 They showed cell death occurred 
through intrinsic and extrinsic apoptotic pathways in response to mitochondrial 
function at low concentrations. Furthermore, they illustrated translatability to in 
vivo models with statistically significant reduction in tumor volume of TNBC MDA-
MB-231 xenograft model at doses as low as 10mg/Kg.116 
 
Figure 2.14: Structure of ESC8 
2.1h Mitochondrial targeting agents with Quaternary salts 
Several types of cancers have shown significantly increased mitochondrial 
membrane potential compared to normal cells. One explanation for increased 
mitochondrial potential is the higher energetic demands of cancerous cells. From 
a therapeutic aspect, this increased potential allows for the development of 
specific mitochondrial-targeting compounds. Of specific interest is the disruption 
of the mitochondrial potential. Currently several classes of compounds have been 
shown to disrupt mitochondrial potential including triphenylphosphoniums, 
guanidiniums, triethylammoniums, pyridiniums, 3-phenylsulfonylfuroxans, 2,3-
dimethylbenzo thiazoliums, rhodamine 19, rhodamine 123 and dequalinium 
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(Figure 2.15).117 A conserved feature of these classes of compounds are they 
contain a lipophilic moiety connected to a delocalizable cation. 
 
Figure 2.15: Examples of mitochondrial targeting agents. 
2.2 Results and Discussion 
2.2a Synthesis of piperazine substituted curcumin analogs 
For modification of phenol, we intended to include a functional group that not only 
maintained electron donating properties, but also allowed for further 
modifications. In this regard, we chose to substitute the phenolic group with 
piperazines. In addition to allowing for further modifications, piperazines also help 
to increase water solubility. To introduce the piperazine unit, we first started with 
ipso substitution of 4-fluoro benzaldehyde with different N-substituted 
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piperazines to obtain corresponding piperizinyl benzaldehydes. These 
piperazinyl benzaldehydes were further condensed with 2,4-pentanedione in the 
presence of boron oxide, triethylborate, and piperadine to yield corresponding 
curcuminoids 2d-2f. (Scheme 2.10) 
 Owing to the relevance of curcumin, we endeavored the synthesis of 
curcumin analogs. Since the solubility is one of the major hurdles, solubility 
enhancing piperazine curcuminoids were synthesized. Initial synthesis of 
piperazinyl benzaldehydes were achieved by ipso substitution of fluoro 
benzaldehyde with three different piperazines namely N-methyl piperizine, N-
ethanol piperizine and N-benzyl piperizine. The usual reaction conditions involve 
refluxing aldehyde along with piperizine and potassium carbonate in DMSO 
solvent. The pure aldehydes were obtained by diluting the reaction in water and 
filtration of the resulting solid product. 
Synthesis of piperazines appended curcumins started by heating 1,4-
pentanedione and boric anhydride at high temperature in DMF. This process of 
heating deactivates the central carbon by forming borate adduct on 1,4-
pentanedione. The reaction was cooled to 120oC and corresponding aldehyde 
was added followed by dropwise addition of an amine base piperidine in DMF. 
Upon the completion of the reaction, solid product was obtained by adding cold 














2.2b Cell proliferation/cytotoxicity study of compounds 2d-2f  
We hypothesized that these modifications would increase water solubility 
and potency. Therefore, we first evaluated these compounds for their ability to 
inhibit cell proliferation. Initial cell proliferation studies of the synthesized 
compounds 2d-2f were carried out using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. This colorimetric assay measures the 
reduction of MTT to formazan by cellular mitochondrial reductase as a measure 
of cell viability. For this assay, we utilized three cell lines including, murine 
metastatic breast cancer cell line 4T1, human breast cancer cell line MDA-MB-
231, and human pancreatic cell line MIAPaCa-2. The new compounds 2d-2f did 
not exhibit toxicity up to 100 µM, whereas the parent compound curcumin has 
activity on these cell lines between 10 and 20 µM.  
 
2.2c Design of novel water soluble curcuminoids as potential anticancer 
agents 
Although curcumin has a lot of potential as therapeutic, it suffers from several 
drawbacks to be a lead compound for clinical applications. Inhibitory 
concentrations on molecular targets only exist at high micromolar concentrations. 
Curcumin is extremely limited in its bioavailability and metabolic stability. 
Therefore, modifications of curcumin should address the metabolically vulnerable 
sites, increase potency, water solubility, and absorption. In this regard, we 
modified curcumin’s free phenol groups to increase metabolic stability and 
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incorporated quaternary ammonium salts for solubility, and introduced Michael 
acceptors for increased potency.  
Our initial modifications helped to increase water solubility and metabolic 
stability but resulted in reduced potency. To help achieve increased potency, we 
envisioned the inclusion of Michael acceptors on our curcuminoid scaffold. 
Michael acceptors are known to be good covalent linkers and can irreversibly 
bind to proteins, mitochondria, and DNA. In this regard, we developed novel 
Michael acceptors with high structural tunability using a Baylis-Hillman reaction 
template. This reaction is simple to perform, and by reacting an aldehyde with 
electron withdrawing group substituted ethylenes such as acrylates, and 
acrylamides in the presence of a nucleophilic base 1,4-diazabicyclo[2.2.2]octane 
(DABCO) provides functionalized allyl alcohols in one step. Furthermore, 
conversion of allylic alcohols to allylic bromides was achieved with either PBr3 or 
H2SO4/HBr (Scheme 2.11). 
 
Scheme 2.11: Synthesis of Baylis Hillman bromides 
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As previously mentioned, we envisioned the inclusion of these Michael 
acceptors to our curcumin scaffold. To achieve this, we utilized our N-methyl 
curcuminoids as a representative example. To incorporate the bromides, the 
curcuminoid was dissolved in DMF and reacted with the corresponding bromide 
to obtain quaternary ammonium piperazinyl curcuminoids. Our design included 
acrylates of varying lengths to investigate the role of lipophilicity played in potency 
of the synthesized derivatives. We also intended to evaluate the necessity of our 
functionalized group in exhibiting SN2 and SN2’ reactivity and generated 
quaternary ammonium salts with allyl and benzyl bromides in this regard 
(Scheme 2.12, Figure 2.16).  
 








2.2d Cell proliferation/cytotoxicity study of compounds 2g-2m 
We hypothesized that the inclusion of functionalized allyl bromides to our 
modified piperazinyl curcuminoids in the form of quaternary ammonium salts 
would increase potency and further increase solubility with SN2 and SN2’ 
capability. 
Cell proliferation studies of the synthesized compounds 2g-2m were 
carried out using in vitro cell proliferation using 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. This colorimetric assay measures the 
reduction of MTT to formazan by cellular mitochondrial reductase as a measure 
of cell viability. For this assay, we utilized three cell lines including, murine 
metastatic breast cancer cell line 4T1, human breast cancer cell line MDA-MB-
231, and human pancreatic cell line MIAPaCa-2. The new compounds 2g and 2h 
containing simple allyl and benzyl salts did not exhibit cell proliferation inhibition 
up to 100 µM concentration, similar to piperazine curcuminoids 2d-2f, whereas 
the ammonium salts containing Baylis-Hillman groups exhibited good activity 
(Table 2.1). Compound 2i exhibited the most potent cell proliferation inhibition 
properties with IC50 values of 3.6, 2.7, and 4.1 µM on MDA-MB-231, MIAPaCa-
2, and 4T1 cell lines, respectively. We also observed that with an increase in the 
carbon chain on the acrylates, the activity was also deceased. To further 
investigate the structure activity of our functionalized curcuminoids, we included 
a phenyl group on the olefin which resulted in decreased activity (Table 2.1, 
Figure 2.17). Lastly, in the modification to include acrylamide instead of 
acrylates, the activity was substantially decreased. It is still noteworthy that all the 
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functionalized allylic salts still resulted in increased potency compared to 
curcumin.  
Table 2.1: Cell proliferation inhibition activity of 2g-2m in MDA-MB-231, 










2g Allyl >100 >100 >100 
2h Benzyl >100 >100 >100 
2i 
 
3.6±0.7 2.7±0.5 4.1±1.1 
2j 
 
3.7±0.8 4.4±0.4 4.1±1.6 
2k 
 
4.2±0.5 4.2±0.7 3.4±0.8  
2l 
 
15.1±1.8 14.2±0.4 17.2±2.8 
2m 
 































































































Figure 2.17. Cell proliferation inhibition of compounds 2i-2m on 4T1, MDA-MB-
231, and MIAPaCa-2  
To demonstrate the necessity of the curcuminoid scaffold, we synthesized 
analogous quaternary ammonium salts utilizing a chemically simple template of 
N-methylmorpholine. For this purpose, N-methylmorpholine was dissolved in 
diethyl ether and the corresponding bromide was added (Scheme 2.13). The 
resulting morpholino quaternary ammonium salts 2n-2p were obtained in good 
yields (Scheme 2.13). In vitro cell proliferation inhibition of these compounds did 
not indicate any significant activity up to 100 µM concentration. We attribute this 
to highly polar nature due to low carbon content and their inability to cross 





Scheme 2.13. Synthesis of morpholino quaternary ammonium salts.  
2.2e Florescence microscopy study of compound 2i in MIAPaCa-2 cells 
The lead compound 2i exhibited good inhibition of cellular proliferation 
against multiple cancer cell lines and has fluorescent properties. Previously 
mentioned was the ability of quaternary ammonium salts to cause mitochondrial 
dysfunction and damage.  In this regard, we planned to use fluorescence 
microscopy to 1) see if our compound enters the cell 2) localizes in the 
mitochondria and 3) causes mitochondrial disruption. To test the ability of the 
compound 2i to cross the cell membrane and induce mitochondrial damage, we 
utilized MIAPaCa-2 cell line and studied fluorescence by labeling mitochondria 
with MitoTracker Red. MitoTracker Red is dependent upon mitochondrial 
potential and thus a change in fluorescent properties could be indicative of 
mitochondrial damage.  The images were obtained using Nikon epifluorescence 
microscope. These studies indicated that in MIAPaCa-2 cells, compound 2i is 
localized in the mitochondria and surrounding areas (Figure 2.18). It also shows 
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that there is mitochondrial disruption as the mitochondria become less defined 
and organized when exposed to compound. For a comparison, we also treated 
cells with curcumin. However mitochondrial damage was not detected utilizing 
this method.   
 
 
Figure 2.18. Fluorescence microscopy of MIAPaCa-2 cells treated with parent 
curcumin (10uM) and lead candidate 2i salt (10uM) for 24 hours. Note candidate 
2i exhibited fluorescent characteristics when excited using a GFP filter set.  
 
2.2f Systemic toxicity evaluation of compound 2i in CD-1 mice 
Compound 2i showed enhanced inhibition of cancer cellular proliferation 
at low µM concentrations against three cell lines and exhibits increased water 
solubility compared to the natural product curcumin. Therefore, we chose to 
evaluate the systemic toxicity of the lead compound 2i in healthy CD-1 mice.  
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Compound 2i was dissolved in a 10% DMSO-saline solution. Toxicity 
study was carried out with mice randomly assigned into 2 groups (n = 6 mice per 
group) with similar average body weights. First group was treated with compound 
2i at 30 mg/Kg, ip, bid for the first 7 days and the dosage was increased to 
50mg/Kg ip bid for an additional 7 days. The control group was administered with 
vehicle (10% DMSO-saline solution). At the end of the study, the treatment group 
did not show any visible toxic effects such as abnormal grooming, hunchback, 
morbidity and did not exhibit significant differences in body weights compared to 
the control group (Figure 2.19). 
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Figure 2.19: Systemic toxicity study of compound 2i 
 
2.2g Anticancer efficacy of compound 2i in pancreatic cancer MIAPaCa-2 
xenograft model in athymic nude mice 
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 We then evaluated the lead candidate compound 2i for in vivo efficacy in 
pancreatic cancer, MIAPaCa-2 tumor flank model. We selected MIAPaCa-2 cell 
line because this compound showed good in vitro activity and it is a well-
established model. Compound 2i was selected for in vivo anticancer efficacy 
study because of its good cytotoxicity and water solubility. We also included 
gemcitabine, a clinically used chemotherapeutic agent for pancreatic cancer as 
a positive control. 
 5 x 106 MIAPaCa-2 cells in a 1:1 mixture of Matrigel:PBS were inoculated 
onto the flank of female athymic nude mice. After the average tumor volume 
reached ~225 mm3, mice were randomly assigned into 4 groups (n = 6 mice per 
group). Group 1 was treated with compound 2i at a dose of 40mg/Kg i.p bid. 2i, 
group 2 was administered gemcitabine at 100mg/Kg, i.p, twice weekly, group 3 
received the same dosages of compound 2i and gemcitabine as a combination 
for 21 days. Group 4 was assigned as a control group and was treated with 
vehicle (10% DMSO). Body weights and tumor volume were measured every 2-
3 days and after 14 days of treatment, mice were euthanized, and tumors were 
resected and weighed.  
From this study, 2i showed a statistically significant reduction of tumor 
volume (P < 0.05) 43% compared to control. This reduction was same as that of 
the clinically used gemcitabine. At the end of, the study, mice were euthanized, 
tumors were resected and weighed. Compound 2i showed tumor reduction by 
42% compared to control as a single agent and a reduction of 57% in combination 
with gemcitabine (Figure 2.20).  
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Figure 2.20: Tumor growth inhibition study of 2i in MIAPaCa-2 flank xenograft 
study  
2.3 Conclusions 
 In conclusion, we modified a natural product curcumin to increase its 
potency and solubility. Evaluation of these curcuminoids showed good cell 
proliferation inhibition on three cell lines of different cancer types, murine 
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metastatic breast cancer cell line 4T1, human TNBC cell line MDA-MB-231, and 
human pancreatic cancer cell line MIAPaCa-2. After demonstrating inhibition of 
cellular proliferation, we translated these results in to in vivo models. For this, we 
first evaluated systemic toxicity in CD-1 mice for compound 2i and found no 
significant body weight changes.  
Anticancer efficacy studies in pancreatic cancer cell line MIAPaCa-2 showed that 
the lead candidate compound 2i reduced the tumor burden at a dosage of 
40mg/Kg ip bid as a single agent. Compound 2i showed greater reduction when 
given with clinically used gemcitabine. Further investigations of these compounds 






Synthesis of 4-(4-methylpiperazin-1-yl)benzaldehyde 
To a solution of 4-fluorobenzaldehyde (10 mmol) in 20 mL DMSO, was 
added N-Methylpiperazine (40 mmol), potassium carbonate (20 mmol), and 
heated for 12hrs at 80 oC. Upon the completion of the reaction, the reaction 
mixture was extracted with ethyl acetate and water. The organic layer was dried 
with anhydrous Mg2SO4 and evaporated to obtain 4-(4-methylpiperazin-1-
yl)benzaldehyde.  
 
Synthesis of 4-(4-(2-hydroxyethyl)piperazin-1-yl)benzaldehyde 
 
To a solution of 4-fluorobenzaldehyde (10 mmol) in 20 mL DMSO, was 
added 2--hydroxyethylpiperazine (40 mmol), potassium carbonate (20 mmol), 
and heated for 12hrs at 80 oC. Upon the completion of the reaction, the reaction 
mixture was extracted with ethyl acetate and water. The organic layer was dried 







Synthesis of (1E,4Z,6E)-5-hydroxy-1,7-bis(4-(4-methylpiperazin-1-yl)phenyl) 
hepta-1,4,6-trien-3-one:  
To a solution of acetylacetone (10 mmol) in DMF (5 mL) was added boric 
anhydride (10 mmol) and the reaction mixture was heated at 170 °C for 0.5 h. 
The reaction was then cooled to 120 °C and 4-(4-methylpiperazin-1-
yl)benzaldehyde (20 mmol) was added. A 1:1 mixture of piperidine (10 mmol) in 
DMF was then added drop wise and the reaction was stirred for 2 h. Upon the 
completion of the reaction (TLC), cold water (20 mL) was added and the solid 
was filtered and washed with water (3 × 20 mL). 5 was obtained as the pure 
compound upon recrystallization in ethyl acetate–methanol mixture. 
 
(1E,4Z,6E)-5-hydroxy-1,7-bis(4-(4-methylpiperazin-1-yl)phenyl)hepta-1,4,6-
trien-3-one 1H NMR (500 MHz, CDCl3): δ ppm 7.59 (d, J = 15 Hz, 2H), 7.46 (d, 
J = 10 Hz, 4H), 6.88 (d, J = 10 Hz, 4H), 6.46 (d, J = 15 Hz, 2H), 5.75 (s, 1H), 3.32 
(t, J = 5 Hz, 8H), 2.58 (t, J = 5 Hz, 8H), 2.36 (s, 6H); 13C NMR (125 MHz, CDCl3): 
δ ppm 183.27, 152.12, 140.19, 129.61, 125.82, 120.68, 115.03, 101.16, 54.73, 
47.71, 45.97.  






To a solution of acetylacetone (10 mmol) in DMF (5 mL) was added boric 
anhydride (10 mmol) and the reaction mixture was heated at 170 °C for 0.5 h. 
The reaction was then cooled to 120 °C and 4-(4-(2-hydroxyethyl)piperazin-1-
yl)benzaldehyde (20 mmol) was added. A 1:1 mixture of piperidine (10 mmol) in 
DMF was then added drop wise and the reaction was stirred for 2 h. Upon the 
completion of the reaction (TLC), cold water (20 mL) was added and the solid 
was filtered and washed with water (3 × 20 mL). (1E,4Z,6E)-5-hydroxy-1,7-bis(4-
(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)hepta-1,4,6-trien-3-one as the pure 




hydroxyhepta-1,4,6-trien-3-one, bromide salt 
To a solution of (1E,4Z,6E)-5-hydroxy-1,7-bis(4-(4-methylpiperazin-1-yl)phenyl) 
hepta-1,4,6-trien-3-one (10 mmol) in DMF (60 mmol) was added the allyl bromide 
(50 mmol) and the reaction mixture was stirred  at RT for 1 hour. Upon the 
completion of the reaction, acetone (20 mL) was added and the resulting 
dibromide salt of (1E,4Z,6E)-5-hydroxy-1,7-bis(4-(4-methylpiperazin-1-






5-hydroxyhepta-1,4,6-trien-3-one, bromide salt 
To a solution of (1E,4Z,6E)-5-hydroxy-1,7-bis(4-(4-methylpiperazin-1-yl)phenyl) 
hepta-1,4,6-trien-3-one (10 mmol) in DMF (60 mmol) was added the benzyl 
bromide (50 mmol) and the reaction mixture was stirred  at RT for 1 hour. Upon 
the completion of the reaction, acetone (20 mL) was added and the resulting 
dibromide salt of (1E,4Z,6E)-5-hydroxy-1,7-bis(4-(4-methylpiperazin-1-
yl)phenyl)hepta-1,4,6-trien-3-one was filtered.  
1H NMR (500 MHz, DMSO-d6) δ ppm 7.65 (d, J=9 Hz,4H), 7.55 (d, J=16 Hz, 2H), 
7.05 (d, J= 9 Hz, 4H), 6.75 (d, J=16 Hz, 2H), 6.11-6.04 (m, 3H), 5.70-5.65 (m, 
4H), 4.16 (d, J=13 Hz, 4H), 3.77-3.36 (m, 16H), 3.12 (s, 6H) 
13C NMR (126 MHz, DMSO-d6) δ ppm 183.5, 151.1, 140.5, 130.3, 128.5, 126.1, 








1H NMR (500 MHz, DMSO-d6) δ ppm 2.86 (br. s., 5 H) 3.43 (br. s., 8 H) 3.60 (d, 
J=13 Hz, 3 H) 3.86 (s, 5 H) 4.66 (br. s., 3 H) 6.02 (s, 1 H) 6.73 (d, J=15 Hz, 1 H) 
6.96 (d, J=8 Hz, 3 H) 7.46 - 7.57 (m, 9 H) 7.60 (br. s., 9 H) 8.37 (s, 2 H);  
13C NMR (126 MHz, DMSO-d6) δ ppm 39.7, 41.3, 45.5, 53.4, 58.1, 59.2, 79.7, 
115.3, 120.8, 126.1, 129.7, 134.0, 140.5, 150.9, 152.0, 167.4, 183.5 
HRMS (ESI) m/z: calc’d for C51H58N4O6 [M/2] :  411.2178, found 411.2202 
 
Synthesis of dimethyl 2,2'-(((((1E,3Z,6E)-3-hydroxy-5-oxohepta-1,3,6-triene-1,7-
diyl)bis(4,1-phenylene))bis(1-methyl-1λ4-piperazine-4,1-diyl))bis(methylene)) 
diacrylate, bromide salt 
To a solution of (1E,4Z,6E)-5-hydroxy-1,7-bis(4-(4-methylpiperazin-1-
yl)phenyl)hepta-1,4,6-trien-3-one (10 mmol) in DMF (60 mmol) was added the 
alkyl bromide (50 mmol) and the reaction mixture was stirred  at RT for 1 hour. 
Upon the completion of the reaction, acetone (20 mL) was added and the 





1H NMR (500 MHz, DMSO-d6) δ ppm 8.33 (s, 1H), 7.63 (d, J = 9 Hz, 4H), 7.55 
(d, J = 16 Hz, 2H), 7.06 (d, J = 9 Hz, 4H), 6.85 (s, 2H), 6.75 (d, J = 16 Hz, 2H), 
6.50 (s, 2H), 6.04 (s, 1H), 4.42-3.85 (m,10H), 3.78-3.49 (m, 16H), 3.10 (s, 6H) 
13C NMR (126 MHz, DMSO-d6) δ 183.5, 166.1, 162.8, 151.1, 141.7, 140.5, 
130.3, 128.8, 126.1, 121.3, 115.4, 62.6, 59.2, 53.2, 45.8, 41.4 
HRMS (ESI) m/z: calc’d for C39H50N4O6 [M]+:  830.2077, found C39H50N4O6 [M-
2Br]+ :  335.1716 
Synthesis of dibutyl 2,2'-(((((1E,3Z,6E)-3-hydroxy-5-oxohepta-1,3,6-triene-1,7-
diyl)bis(4,1-phenylene))bis(1-methyl-1λ4-piperazine-4,1-diyl))bis(methylene)) 
diacrylate, bromide salt 
To a solution of (1E,4Z,6E)-5-hydroxy-1,7-bis(4-(4-methylpiperazin-1-yl)phenyl) 
hepta-1,4,6-trien-3-one (10 mmol) in DMF (60 mmol) was added the alkyl 
bromide (50 mmol) and the reaction mixture was stirred  at RT for 1 hour. Upon 
the completion of the reaction, acetone (20 mL) was added and the resulting 
dibromide salt, dibutyl 2,2'-(((((1E,3Z,6E)-3-hydroxy-5-oxohepta-1,3,6-triene-1,7-
diyl)bis(4,1-phenylene))bis(1-methyl-1λ4-piperazine-4,1-






1H NMR (500 MHz, DMSO-d6) δ ppm 7.62 (d, J= 8 Hz,4H), 7.54 (d, J= 16 Hz, 
2H), 7.03 (d, J= 8 Hz, 4H), 6.84 (s, 2H), 6.73 (d, J= 16 Hz, 2H), 6.49 (s, 2H), 6.04 
(s,1H), 4.42(s, 4H), 4.17 (t, J= 7Hz, 4H), 3.84(d, J= 12Hz, 4H), 3.55-3.52(m, 12H), 
3.07 (s, 6H), 1.65-1.60 (m, 4H), 1.38-1.34 (m, 4H), 0.90 (t, J=8 Hz, 6H)   
13C NMR (126 MHz, DMSO-d6) δ ppm 183.6, 165.7, 151.1, 141.5, 140.5, 130.3, 
129.0, 126.1, 121.3, 115.4, 101.6, 65.7, 62.6, 59.2, 45.8, 41.4, 30.5, 19.1, 14.1 
HRMS (ESI) m/z: calc’d for C45H62N4O6 [M/2] :  377.2335, found 377.2273 
Synthesis of dihexyl 2,2'-(((((1E,3Z,6E)-3-hydroxy-5-oxohepta-1,3,6-triene-1,7-
diyl)bis(4,1-phenylene))bis(1-methyl-1λ4-piperazine-4,1-diyl))bis(methylene)) 
diacrylate, bromide salt 
To a solution of (1E,4Z,6E)-5-hydroxy-1,7-bis(4-(4-methylpiperazin-1-yl)phenyl) 
hepta-1,4,6-trien-3-one (10 mmol) in DMF (60 mmol) was added the alkyl 
bromide (50 mmol) and the reaction mixture was stirred  at RT for 1 hour. Upon 
the completion of the reaction, acetone (20 mL) was added and the resulting 
dibromide salt, dihexyl 2,2'-(((((1E,3Z,6E)-3-hydroxy-5-oxohepta-1,3,6-triene-
1,7-diyl)bis(4,1-phenylene))bis(1-methyl-1λ4-piperazine-4,1-




1H NMR (500 MHz, DMSO-d6) δ ppm 7.63 (d, J= 8 Hz, 4 H), 7.55 (d, J= 16 Hz, 
2H), 7.05(d, J= 8Hz, 4H), 6.84 (s, 2H), 6.75 (d, J= 16 Hz, 2H), 6.53 (s, 2H) 6.05 
(s, 1H), 4.46 (s, 4H), 4.17 (t, J= 7 Hz, 4H), 3.85 (d, J= 11 Hz, 4H), 3.55-3.53 
(m,12H), 3.10 (s, 6H), 1.66-1.62 (m, 4H), 1.34-1.27 (m, 12H), 0.85 (t, J= 7 Hz, 
6H)   
 
13C NMR (126 MHz, DMSO-d6) δ ppm 183.6, 165.6, 151.1, 141.4, 140.5, 130.3, 
129.0, 126.1, 121.3, 115.4, 105.0, 66.0, 62.7, 59.2, 45.9, 41.4, 31.3, 28.4, 25.5, 
22.4, 14.4  
 
HRMS (ESI) m/z: calc’d for C49H70N4O6 [M/2] :  405.2642, found 405.2637 
 
Synthesis of 2,2'-(((((1E,3Z,6E)-3-hydroxy-5-oxohepta-1,3,6-triene-1,7-diyl)bis 
(4,1-phenylene))bis(1-methyl-1λ4-piperazine-4,1-diyl))bis(methylene) )bis(N,N-
dimethylacrylamide), bromide salt 
To a solution of (1E,4Z,6E)-5-hydroxy-1,7-bis(4-(4-methylpiperazin-1-yl)phenyl) 
hepta-1,4,6-trien-3-one (10 mmol) in DMF (60 mmol) was added the alkyl 
bromide (50 mmol) and the reaction mixture was stirred  at RT for 1 hour. Upon 









1H NMR (500 MHz, DMSO-d6) δ ppm 7.64 (d, J= 8Hz, 4H), 7.55 (d, J= 16 Hz, 
2H), 7.05 (d, J= 8Hz, 4H), 6.75 (d, J= 16 Hz, 2H), 6.11 (s, 2H), 6.04 (s, 1H), 5.94 
(s, 2H), 4.44 (s, 4H), 3.81-3.78 (m, 4H), 3.60-3.10 (m, 24H), 2.92 (s, 6H) 
13C NMR (126 MHz, DMSO-d6) δ ppm 183.5, 168.4, 151.0, 140.5, 132.4, 132.3, 
130.3, 126.1, 121.3, 115.4, 101.6, 64.9, 59.1, 46.5, 41.4, 35.4 
HRMS (ESI) m/z: calc’d for C41H56N6O4 [M/2] :  348.2181, found 348.2060 
 
Synthesis of dimethyl 2,2'-(((((1E,3Z,6E)-3-hydroxy-5-oxohepta-1,3,6-triene-1,7-
diyl)bis(4,1-phenylene))bis(1-methyl-1λ4-piperazine-4,1-diyl))bis(methylene)) 
(2Z,2'Z)-bis(3-phenylacrylate) 
To a solution of (1E,4Z,6E)-5-hydroxy-1,7-bis(4-(4-methylpiperazin-1-yl)phenyl) 
hepta-1,4,6-trien-3-one (10 mmol) in DMF (60 mmol) was added the alkyl 
bromide (50 mmol) and the reaction mixture was stirred  at RT for 1 hour. Upon 
the completion of the reaction, acetone (20 mL) was added and the resulting 
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dibromide salt, dimethyl 2,2'-(((((1E,3Z,6E)-3-hydroxy-5-oxohepta-1,3,6-triene-
1,7-diyl)bis(4,1-phenylene))bis(1-methyl-1λ4-piperazine-4,1-






1H NMR (500 MHz, DMSO-d6) δ 8.37 (s, 2H), 7.39 - 7.71 (m, 17H), 6.96 (d, J = 
8 Hz, 4H), 6.73 (d, J = 16 Hz, 2H), 6.02 (br. s., 1H), 4.66 (s, 4H), 3.86 (s, 6H), 
3.60 (d, J = 13 Hz, 6H), 3.10-3.49 (m, 4H), 2.86 (s, 6H), 2.49 (s, 6H) 
13C NMR (126 MHz, DMSO-d6) δ 183.5, 167.4, 152.0, 150.9, 140.5, 134.1, 130.5, 
130.2, 129.7, 126.2, 121.4, 120.8, 115.3, 101.6, 59.2, 53.4, 45.4, 41.3 
HRMS (ESI) m/z: calc’d for C51H58N4O6 [M/2] :  411.2178, found 411.2202 
2.4b Cell lines and culture conditions 
4T1 cells were purchased from Caliper Life Sciences and were cultured in 




MDA-MB-231 cells were purchased from ATCC and were cultured in 
DMEM supplemented with FBS (10%, Atlanta Biologicals) and penicillin-
streptomycin (50 U/mL, 50 µg/mL, Invitrogen).  
MIAPaCa-2 cells were purchased from ATCC and were cultured in DMEM 
supplemented with FBS (10%, Atlanta Biologicals), Horse serum (1% Atlanta 
Biologicals), and penicillin-streptomycin (50 U/mL, 50 µg/mL, Invitrogen).  
 
2.4c MTT assay 
Cells (5 x 103 cells/well) were cultured in 96-well plates and incubated for 
18-24 hours. Stock solution of compound was made up at 100 mM concentration 
in DMSO. The final concentration of DMSO in the wells were < 0.01%. 
Concentration range of compounds from 100 µM to 0.1 µM was tested by adding 
2x concentration of test compound to the first well and then the serial dilutions by 
going from well to well. All the compounds were tested in duplicates. After 72 
hours of treatment, 10 µL of MTT (5 mM in 1x PBS) was added into the wells and 
the cells were incubated for a period of 4 hours. At this point, the conversion of 
MTT to formazan was quenched by the addition of 100 µL of SDS (1 g of SDS 
dissolved in 0.01 N HCl) and the cells were incubated for further 4 hours. The 
absorbance was recorded at 570 nm using BioTek Synergy 2 plate reader. The 
absorbance is directly proportional to the cell viability. % Survival was calculated 
using the formula  




IC50 was calculated using GraphPad Prism software, by plotting a dose-
response curve with log[concentration] on x-axis and % survival on y-axis and 
analyzing via nonlinear regression with variable slope. 
 
 
2.4d Florescence microscopy study 
The cells (2 mL) were seeded at a concentration of 5x104 cells/mL in a 2 
cm MatTek (MatTek Corp, #P35G010C) culture dish with glass bottom and were 
incubated at 37oC in 5% CO2 atmosphere for 48 hours. The growth medium was 
removed and 2 mL of fresh growth medium with compound 2i was added to the 
culture dish. The cells were incubated for a period of one hour, and the medium 
was aspirated and washed once with 5% FBS in 1X PBS solution, and further 2 
mL of 5% FBS was added to the culture dish. The cells were then imaged to 
observe the localization of compound in the cells. In the case of MitoTracker Red 
CMXROS (Invitrogen, M7512), the compound was incubated for 45 minutes, and 
a 20 µL solution of mitotracker red (100 nM) was added to the cells and further 
incubated for 15 minutes and cells were washed and replaced with 5% FBS 
solution for imaging.  
2.4e Ethical Considerations for animal studies 
The experimental procedures involving animals that were conducted at the 
University of Minnesota Duluth were in compliance with the U.S. National 
Institutes of Health Guide for Care and Use of Laboratory Animals and approved 
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by the Institutional Animal Care and Use Committee at the University of 
Minnesota (UMN).  
 
2.4f General procedure for systemic toxicity evaluation 
 Mice were procured from Charles River, and acclimatized at room 
temperature for a period of 7 days. The mice were weighed and randomized into 
groups (n = 6 mice per group) based on same average weights. Mice were 
housed as two mice per cage. Treatment was started via i.p. and body weights 
were monitored for a period of 14-21 days. At the end of the study, mice were 
euthanized using CO2.  
 
2.4g Anticancer efficacy of compound 2i in MIAPaCa-2 flank model 
5 x 106 MIAPaCa-2 cells were suspended in a mixture of 1:1 matrigel-PBS 
(100µL). These cells were then injected subcutaneously onto the right flank of 
aythamic nude mice and tumors were measured via calipers and the tumor 
volume was calculated using the formula 
𝑉 =  
1
2
× 𝑎 × 𝑏2  
where ‘a’ is the long diameter of the tumor and ‘b’ is the short diameter of the 
tumor.  Mice were assigned into groups (n = 8 mice per group) when the average 
tumor volume reached ~100-200 mm3 and the treatment was initiated and 
continued for a period of 21 days. Tumor volume was recorded every 2-3 days 
and at the end of the study, mice were euthanized, and tumors were resected 
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× 100  
where C is average tumor weight of the control group and T is the average tumor 










































































































































































CHAPTER 3: Synthesis and Biological Evaluation of Chalcone Appended 
Cyanoacrylic acids as Anticancer Agents 
3.1 Introduction 
3.1a Evolution of hallmarks of cancer: A focus on tumor metabolism 
In the chapter 1, Hanahan and Weinberg’s summary of major hallmarks of 
cancer was discussed with the focus on angiogenesis and cell signaling. The 
focus of this chapter will be on tumor metabolism or more specifically, cellular 
energetics. Mutational events and the heterogenetic nature of tumors result in 
changes to their cellular metabolism.1,118,119 These changes in cellular 
metabolism play a major role in tumorigenesis. Several studies have shown and 
demonstrated altered cellular metabolism in solid tumors.119,120,129,121–128 As a 
result, the development of therapeutics combating the metabolism of cancer cells 
are highly useful. 
 
3.1b Glycolysis and its relation to Warburg effect 
  Cellular energy is produced through several different metabolic pathways 
including aerobic glycolysis, mitochondrial oxidative phosphorylation (OxPhos), 
glutaminolysis, fatty acid metabolism, etc.117,130–134 In cancer cells, the balance of 
these processes is heavily altered, with many advanced stage tumors relying on 
glycolysis.131,135,136 Glycolysis is a process of metabolism which involves the 
conversion of glucose to lactate and pyruvate. The highly proliferative nature of 
cancerous tumors gives rise to differences in spatial oxygen availability.   These 
spatial differences result in different tumor cell populations being oxygen rich 
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(aerobic) and some being oxygen deficient (hypoxic).118,137 Hypoxic tumor cells 
consume large quantities of glucose producing lactic acid and pyruvic acid as by-
products.120,127,138 The inefficiency of glycolysis results in one mole of glucose 
yielding only two moles of ATP. However, the increased rate of glycolysis in 
hypoxic cells allows for sufficient energy production to sustain cell proliferation 
(Figure 3.1).120,127,138 The glycolytic by-products do not go to waste as nearby 
aerobic cancer cells take up these products to efficiently generate energy through 
mitochondrial oxidative phosphorylation, a process that produces 30-36 moles of 
ATP per mole of starting glucose. As a result, a metabolic symbiosis occurs 
where hypoxic cells take up glucose and provide glycolytic by-products for 
aerobic cells. Overall this cellular specialization results in a very efficient means 
of energy production and is essential to tumor progression. The cellular 
specialization arising from differences in oxygen availability, has led to great 
clinical barriers in tumor treatment and results in failed treatment, patient relapse 
and mortality.132,133,139  
 
 






3.1c Monocarboxylic acid transporters (MCTs) and their importance in 
metabolism 
 
MCTs are a class of proton-linked plasma membrane transporters belonging to 
the SLC16 gene family. The primary role of MCTs is to shuttle small molecules 
such as lactic acid, pyruvic acid and other ketone bodies across biological 
membranes of cells. The MCT family is comprised of 14 known isoforms with 
varying affinities to each of these molecules 140,141. MCT1 and MCT4 have been 
known to be highly involved in metabolic processes. MCT1 is encoded by 
SLC16A1 gene and it is a 40 kDa protein consisting of 12 transmembrane 
domains which are assumed to have hydrophobic α-helical segments. MCT1 has 
intracellular N-terminal and C-terminal with loops spanning across the cellular 
transmembrane. Although the crystal structure of MCT1 is unknown, a few 
homology models have been proposed. MCT1 is ubiquitously distributed 
throughout the body and is overexpressed in many cancer types, making it an 
intriguing therapeutic target. MCT1 plays a major role in the export of lactic acid 
out of hypoxic cells where MCT4 can import lactic acid to nearby aerobic cells.140  
Shuttling of lactic acid outside of the highly glycolytic cells via MCT1 will prevent 
apoptosis from cellular acidosis, and give substrates for aerobic cells to generate 
energy from. Similarly, MCT4s role in the import of lactate plays an essential role 
in relieving the acidic environment from hypoxic regions and proving the fuel for 
the aerobic cells.141 Due to their importance in the influx and efflux of metabolites 
for energy production, MCT1 and MCT4 can be considered as important targets 
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for cancer treatment.142–147 Inhibition of MCT1 and/or MCT4 results in the 
decrease of intracellular pH leading to cell acidosis, and eventually, aerobic cells 










3.1d Mitochondrial pyruvate carriers 
Mitochondrial pyruvate carriers (MPCs) are on the inner mitochondrial membrane 
and function to connect glycolysis to OxPhos. MPCs are responsible for carrying 
pyruvate from the cytosol to the mitochondria.135,148 The loss of MPC activity has 
been found to promote glycolysis or Warburg-like metabolic profile in various 
tumor models.135,148 Overexpression of MPC has been correlated with negative 
patient outcomes in several tumor types. Inhibition of MPC results in an increase 
of mitochondrial ROS and triggering of apoptosis pathway.135,148–151 
 
3.1e CHC as MCT1 inhibitor  
Since Hanahan and Weinberg reported cellular energetics as a hallmark 
of cancer, there has been a huge interest in developing glycolysis inhibitors as 
anticancer therapies. In this regard, α-cyano-4-hydroxy cinnamic acid (CHC, 
Figure 3.3) was first reported to be an inhibitor of MCT1. Since then, CHC has 
also been reported as a plant growth regulator and a mitochondrial pyruvate 
carrier inhibitor.133 
 




CHC was able to inhibit the growth of U87-MG glioblastoma cells injected 
into rats.152 For this study, tumors were implanted and allowed to grow for 
fourteen days. At which point an osmotic pump was implanted and CHC was 
directly given to the tumor site. Half of the mice that received treatment were able 
to survive for 120 days, illustrating that CHC can significantly increase the 
survival of glioma in vivo. Histological analysis showed treated tumors underwent 
necrosis while healthy brain tissue surrounding the tumor were unaffected. 
Several more recent studies have demonstrated CHC’s ability in reducing tumor 
burden in wide variety of cancers.149,153–156 These results support the hypothesis 
that MCT inhibitors can be used as therapeutic agents for the treatment of 
cancers. 
 
3.1f SAR studies on CHC 
Previous work in our lab involved the synthesis and evaluation of novel 
MCT1/4 inhibitors as potential anticancer agents. To generate a large library of 
CHC derivatives, Mereddy’s lab took a variety of benzaldehydes and performed 





Scheme 3.1: Knoevenagel condensation of substituted benzaldehydes with 
cyanoacetic acid to form CHC based derivatives. 
 
Initial modifications of the benzaldehydes included substitution of p-
hydroxyl group in CHC with electron withdrawing groups such as halides, CN, 
and NO2 and electron donating groups such as methoxy, 3,4-methylenedioxy, 
alkyl, and N,N-dialkyl groups. Testing of these compounds for MCT1 inhibition 
showed that the N,N-dialkyl derivatives were the most potent. The potency of the 
N,N-dialkyl derivatives was dependent upon chain length, such that increasing 
chain length from methyl to butyl increased activity, however further extension 
resulted in a loss of activity. Similarly, we found that the substitution on nitrogen 
with phenyl and benzyl groups also resulted in good activity.156,157 After 
optimization of the para position, we investigated substitutions in ortho position. 
In this case metoxy group was introduced (Scheme 3.2).  
 
Scheme 3.2: A representative scheme for the synthesis of the library of N,N-




Lactate uptake inhibition studies showed inclusion of a methoxy group 
further enhanced activity against MCT1 and MCT4 (Scheme 3.2 and Figure 3.4). 
Modifications of the cyano, carboxylic acid, and α,β-unsaturation resulted in a 
loss of activity (data not shown). Furthermore, these derivatives were able to 
significantly reduce the tumor burden of various tumor models in vivo.156,157 
 
 
Figure 3.4: The SAR study of the N,N-dialkyl/diaryl substituted CHC derivatives 
 
3.1g Other MCT1 inhibitors  
Utilizing MCT1 as a potential target for therapeutic intervention is actively 
being investigated by other labs for the development of chemotherapeutics. 
AstraZeneca has developed a series of MCT1 inhibitors and selected AZD3965 
as a lead compound.158–162 AZD3965 was shown to be selective towards MCT1 
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and has no activity towards MCT4 (Figure 3.5).158–162 The MCT1 efficacy was 
evaluated using L-lactate transport study on rat erythrocytes and xenopus 
oocytes. Furthermore, AZD3965 was tested in vivo with COR-L103 which was 
isolated from human lung small cell carcinoma. AZD3965 also exhibited 
significant tumor growth inhibition in other tumor models. Dosing of AZD3965 at 
100mg/kg compound exhibited ~60% tumor growth inhibition.158–162 It is now 
currently in phase-I clinical trials for diffuse large B-cell lymphoma, Burkitt 
lymphoma, and other solid tumors.  
 
 
Figure 3.5: Structure of AZD3965  
3.1j Pyrazole methylpropanoic acid derivatives as MCT4 inhibitors 
Not only have compounds been developed for the inhibition of MCT1 but 
interest in developing selective MCT4 inhibitors has arose. SAR studies have 
identified therapeutics that are selective to MCT4 transporters.142 One class of 
reported MCT4 inhibitors are 2-((1-(2-chlorobenzyl)-5-(3-substituted phenyl)-1H-
pyrazol-3-yl)methoxy)-2-methylpropanoic acids (Figure 3.6). These derivatives 
exhibited excellent specificity towards MCT4 activity. These pyrazole derivatives 





Figure 3.6: Lead MCT4 inhibitor 2-((1-(2-chlorobenzyl)-5-(3-substituted phenyl)- 
1H-pyrazol-3-yl)methoxy)-2-methylpropanoic acids 
  
3.1k UK-5099 as mitochondrial pyruvate carrier inhibitor 
UK-5099 (Figure 3.7 is currently being developed as a mitochondrial pyruvate 
carrier inhibitor and is known to have activity against mitochondrial pyruvate 
carriers and MCTs. Potency of UK-5099 was found to be 50nM. As result of the 
good potency studies evaluating mitochondrial function have been carried out. 
Studies reported that 150µM UK-5099 significantly reduced mitochondrial 
ATP.135,149 
 





3.1l Chalcones as a therapeutic agent 
Chalcones, or 1,3-diphenyl-2-propen-1-ones, are a very important class of 
flavonoids. Chalcones are yellow to orange open-chain precursors for 
biosynthesis of flavonoids and isoflavonoids and in nature occur mainly as 
polyphenolic compounds.163,164 They exist as either trans (E, 1) or cis (Z, 2) 
isomers having two aromatic rings that are joined by a three-carbon α,β-
unsaturated carbonyl system (Figure 3.8). 
 
Figure 3.8: Structural template of chalcones 
 
Thermodynamically the E isomer is more stable and thus is the predominant form 
found in nature.164 Chalcones have been found to have many therapeutic 
properties such as anti-inflammatory, anti-microbial, anti-protozoal, anti-malarial, 





Figure 3.9 Biological activities of Chalcones 
Clinically, chalcones have been utilized; For example, metochalcone was 






Figure 3.10: Examples of clinically explored chalcones 
3.1m Synthesis of Chalcones 
Claisen-Schmidt condensation 
The simple chemistry of chalcones allows several different substitutions and a 
wide variety of methods for their synthesis. Typically, chalcone synthesis is 
carried out with a condensation reaction of two aromatic carbonyl systems.  
Claisen-Schmidt condensation is one of the most common methods due to the 
availability of substituted aldehydes and ketones. In this reaction, chalcones are 
formed by condensation of benzaldehyde and acetophenone derivatives in the 
presence of alkaline or acid catalysts in liquid solvent at 50–100 °C for several 
hours (Scheme 3.3).168 
 
Scheme 3.3: The Claisen-Schmidt condensation to synthesize chalcones 
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Carbonylative Heck coupling: In the carbonylative Heck coupling reaction 
chalcones are synthesized with the use of palladium catalyst causing the reaction 
conditions to be more expensive. Palladium catalyzes the vinylation of phenyl 
halides with styrenes in the presence of carbon monoxide (Scheme 3.4).169 
 
Scheme 3.4: Carbonylative Heck coupling reaction to synthesize chalcones 
Sonogashira Isomerization coupling: The Sonogashira isomerization coupling 
method offers less versatility due to the requirement of electron deficient phenyl 
halides. In this reaction, electron deficient phenyl halides are reacted with phenyl 
substituted propargyl alcohols in the presence of PdCl2(PPh3)2 and microwave 
irradiation. Like the carbonylative Heck coupling, this method tends to be more 
expensive and limited in scope (Scheme 5).169 
Scheme 3.5: Sonogashira isomerization coupling to synthesize chalcones 
Suzuki-Miyaura Coupling reaction: Suzuki-Miyaura coupling reaction involves the 
reaction of boronic acids with acid chlorides. The versatility of this reaction is 
conserved with the boronic acid existing as either the phenyl boronic acid or as 
the styryl boronic acid. Similarly, the acid chloride can be prepared as either the 
benzoyl chloride or the cinnamoyl chloride. Once again this reaction requires the 
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use of a palladium catalyst (Pd(PPh)4) increasing the cost of the reaction 
(Scheme 3.6).170 
 
Scheme 3.6: Suzuki-Miyaura coupling reaction to synthesize chalcones 
3.1n Chalcones as natural product and drug candidates:  
Xanthoangelol: Xanthoangelol is a chalcone isolated from Japanese herb 
Angelica keiskei, that exhibits versatile biological and pharmacological activities, 
including anti-inflammatory, anti-microbial, anti-platelet, antioxidant, and 
antidiabetic. Recently, xanthoangelol has been recognized for its anti-cancer 
activity towards a variety of cancer types including osteosarcoma, leukemia, and 
neuroblastoma (Figure 3.11).164,171 Xanthoangelol has been shown to inhibit the 
phosphorylation of Stat3 in LM8 osteosacroma models in mice which resulted in 
suppressed growth and metastasis. In neuroblastoma and leukemia cell lines 
IMR-32 and Jurkat respectively, xanthoangelol induced apoptosis through the 
activation of caspase-3.164,171 Xanthoangelol is also being studied as an aurora 




Figure 3.11: Structure of Xanthoangelol  
3.1o Chalcones as anticancer agents TUB091 and TUB099: Canela, et al. 
reported the synthesis and biological evaluation of novel tubulin binding 
chalcones. They selected TUB091 as a lead derivative and TUB099 as a peptide-
based prodrug (Figure 3.12). These lead compounds showed tubulin binding, 
vascular-targeting, anti-tumor, and anti-metastatic activities on numerous cell 
lines. TUB091 and TUB099 was able to inhibit the proliferation of endothelial and 
tumor cell lines in the 1-4nM range.164,173 CAM assays showed the ability of lead 
compounds to inhibit endothelial cell migration, angiogenesis, and disruption of 
immature capillary networks while leaving mature vasculature intact.  
Furthermore, TUB099 significantly reduced the primary growth of mouse 
melanoma B16-F10-luc2 and human triple negative breast cancer MDA-MB-231 
cells in mice through intratumorally and intraperitoneal administration.164,173 
Immunohistological analysis with Ki67 and CD31 provided evidence TUB099 was 
able to have antiproliferative effects in both models.  
  
 
Figure 3.12: Structure of TUB091 and TUB099 
3.2 Results and Discussion: 
3.2a Synthesis of Chalcone appended cyanoacrylic acid 
176 
 
 The phenylacrylic acids were synthesized starting from commercially 
available substituted acetophenones. For this purpose, we utilized 
acetophenone, 1-(4-fluorophenyl)ethan-1-one and 1-(3,4,5-
trimethoxyphenyl)ethan-1-one. The first step involved condensation of methyl 
ketones with an acetal protected aldehyde, 4-(dimethoxymethyl)benzaldehyde in 
the presence of a base, followed by the deprotection of acetal to obtain the 
corresponding acetophenone-benzaldehydes 3a-3c. The aldehydes were then 
condensed with cyanoacetic acid via Knoevenagel condensation to get the 
corresponding chalcone cyanoacrylic acids 3d-3f (Scheme 3.7).  
 
Scheme 3.7: Synthesis of chalcone substituted cyanocinnamic acids 3d-3f 
 
As we reported previously, presence of doubly activated cyanoacrylic acid unit 
make these compounds powerful 1,4-acceptors but due to the presence of highly 
acidic hydrogen they act as rapid reversible inhibitors. We envisioned that 
introduction of an α,β-unsaturated system similar to that of a chalcone will make 
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these compounds irreversible inhibitors also with metabolic inhibition properties 
(Figure 3.13). 
 
Figure 3.13: Reversible and irreversible units in chalcone cyanocinnamic acid 
structure. 
 
3.2b In vitro MTT based cell proliferation inhibition 
These chalcone cyanoacrylic acids 3d-3f were tested for cell proliferation 
inhibition properties using MTT based assay against MDA-MB-231, WiDr, 4T1 
cell lines and found to be not significantly active up to 50 µM concentration. 
3.2c Seahorse XFe96® analyzer 
The compounds 3d-3f were then evaluated for extracellular flux analysis 
using Seahorse XFe96® analyzer at 100 µM concentration. For this purpose, 
4T1, MDA-MB-231, and WiDr and cell lines were subjected to mitochondrial 
stress test (MST) and glycolytic stress test (GST) according to the manufacturer’s 
protocol. For MST, oxygen consumption rate (OCR) was recorded and the 
following parameters were calculated using wave software based on the OCR 
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values in the presence of different mitochondrial inhibitors: maximal respiration, 
ATP production, proton leak and spare respiratory capacity. Compounds were 
dissolved in DMSO which was used as a negative control. The candidate 
compounds 3d and 3e altered OCR values significantly compared to control in 
all these three cell lines (Figure 3.14).  
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Figure 3.14: Mitochondrial stress test in (A) 4T1, (B) MDA-MB-231 and (C) WiDr 
cell lines using compounds 3d-3e. The OCR values were calculated using wave 
software. The average+SEM values of at least three independent experimental 
values were calculated. 
 
To measure maximal oxygen consumption rate, cells were treated with a 
proton uncoupler, FCCP. FCCP eliminates the proton gradient, perturbing the 
mitochondrial membrane potential. As a result, the electron transport chain works 
to oxidize substrates rapidly to return the membrane potential in the mitochondria, 
which requires a large consumption of oxygen. Thus, the maximum oxygen 
consumption rate that the mitochondria can utilize could be measured. In 4T1 cell 
line, compound 3d significantly reduced maximal oxygen consumption, whereas 
in MDA-MB-231 cell line, compounds 3d and 3e significantly reduced this 
parameter. Compounds 3e and 3f significantly decreased maximal respiration 
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Figure 3.15: Maximal respiration in (A) 4T1, (B) MDA-MB-231 and (C) WiDr cell 
lines using compounds 3d-3f. The OCR values were calculated using wave 
software. The average+SEM values of at least three independent experimental 
values were calculated. 
 
 
ATP production from mitochondria can be determined by observing the 
difference in OCR before and after the addition of an ATP synthase inhibitor, 
oligomycin A. In MDA-MB-231 cell line, all the candidate compound 3d 
significantly reduced ATP production, whereas in 4T1 and WiDr cell line, no 
significant change was observed (Figure 3.16). These results suggest that these 
compounds may affect the mitochondria by interfering with ATP synthase and 














































































































Figure 3.15: Maximal respiration in (A) 4T1, (B) MDA-MB-231 and (C) WiDr cell 
lines using compounds 3d-3f. The OCR values were calculated using wave 
software. The average+SEM values of at least three independent experimental 
values were calculated. 
 
After the addition of oligomycin, proton leak can also be determined. 
Proton leak is the sum of the oxygen consumption from processes outside of ATP 
synthase. Cells with damaged mitochondria have greater amounts of proton leak 
as they are forced to use less efficient pathways to generate ATP. In 4T1 and 
WiDr cell lines, compounds 3d-3f did not show significant changes in proton leak, 
whereas in MDA-MB-231 cell line, candidate compound 3d significantly 
increased proton leak compared to the control (Figure 3.17). These results 
illustrate that compound 3d disrupts the mitochondria proton flux in highly 















































































































Figure 3.17: Proton leak in (A) 4T1, (B) MDA-MB-231 and (C) WiDr cell lines 
using compounds 3d-3f. The OCR values were calculated using wave software. 
The average+SEM values of at least three independent experimental values 
were calculated. 
 
Spare respiratory capacity is calculated from the difference between basal 
oxygen consumption and the consumption of ATP synthase proton uncoupled 
mitochondria. Relevance of measuring spare respiratory capacity explains the 
capability of the cell to respond to an energetic demand. In all cell lines, candidate 
compounds 3d and 3e significantly reduced this spare respiratory capacity 
compared to the control (Figure 3.18). These results show that these compounds 
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Figure 3.18: Spare respiratory capacity in (A) 4T1, (B) MDA-MB-231 and (C) 
WiDr cell lines using compounds 3d-3f. The OCR values were calculated using 
wave software. The average+SEM values of at least three independent 
experimental values were calculated. 
 
Glycolysis stress test in MDA-MB-231 and WiDr cell lines: The glycolysis stress 
test allows us to evaluate glycolysis, glycolytic capacity and glycolytic reserve. 
Measuring the extracellular acidification rate (ECAR) of glucose deprived cells 
allows us to determine basal levels of ECAR. We can then add glucose to the 
cells and measure the ECAR. Glycolysis is defined by this change in ECAR. For 
example, if our test compound inhibits glycolysis, we will see a smaller change in 
ECAR before and after addition of glucose. To force the cells to undergo higher 
rates of glycolysis, we can treat cells with an ATP synthase inhibitor, oligomycin 
A and measure the change in ECAR. Since cells have the same energetic 
demand and mitochondrial function has been inhibited this results in the cells 
undergoing glycolysis at maximum capacity or glycolytic capacity. If our 
compound is active, we expect to see a decrease in the ECAR. The final drug 
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delivery port is injected with glycolysis inhibitor 2-deoxy-glucose. With this 
addition, ECAR is reduced to basal levels and the difference between glycolysis 
and glycolytic capacity can be defined as glycolytic reserve, which indicates the 
flexibility of cells to overcome stressful conditions. 
 
Glycolytic stress test ECAR were measured in real-time, and the 
following parameters were calculated as a result: glycolysis, glycolytic capacity 
and glycolytic reserve. Like the mitochondrial stress test, compounds were 
dissolved in DMSO and as such was used as a negative control. The 
compounds were tested at 100 µM concentration. Although compounds 3e and 
3f only minimally altered ECAR in MDA-MB-231 cell line, in WiDr cell line, these 
compounds 3d and 3e significantly altered the ECAR compared to control 
(Figure 3.19). All the test compounds did not exhibit any effect on ECAR in 4T1 
cell line.
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Figure 3.19: Glycolytic stress test in (A) 4T1, (B) MDA-MB-231 and (C) WiDr cell 
lines using compounds 3d-3f. The ECAR values were calculated using wave 
software. The average+SEM values of at least three independent experimental 
values were calculated. 
 
Glycolysis is the cells ability to convert glucose to pyruvate. To measure 
glycolysis basal extracellular acidification rates in the absence of glucose is 
compared to after the addition of glucose. As glucose is converted extracellular 
acidification rate should increase showing the cells ability to perform glycolysis. 
In 4T1 cell line, none of the compounds showed a significant change. In MDA-
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MB-231 cell line, compound 3d and 3f significantly reduced glycolysis compared 














































































































Figure 3.20: Glycolysis in (A) 4T1, (B) MDA-MB-231 and (C) WiDr cell lines using 
compounds 3d-3f. The ECAR values were calculated using wave software. The 
average+SEM values of at least three independent experimental values were 
calculated. 
 
Glycolytic capacity is the ability of the cells to meet energetic demands 
after the addition of an ATP synthase inhibitor oligomycin A, which disrupts 
oxidative phosphorylation. The addition of oligomycin A results in the cell to 
achieve its theoretical maximum rate of glycolysis. Glycolytic capacity is also the 
difference between basal level before glucose addition and after the cell is in 
crisis (Figure 3.21). None of the tested compounds showed a significant change 















































































































Figure 3.21: Glycolytic capacity in (A) 4T1, (B) MDA-MB-231 and (C) WiDr cell 
lines using compounds 3d-3f. The ECAR values were calculated using wave 
software. The average+SEM values of at least three independent experimental 
values were calculated. 
Glycolytic reserve is the difference of the cells ability to undergo glycolysis 
under normal conditions and after there is an energetic demand (Figure 3.22). 
Therefore, it is a measurement of how closely the glycolytic function is to the 
theoretical maximum. None of the tested compounds showed a significant 










































































































Figure 3.22: Glycolytic reserve in (A) 4T1, (B) MDA-MB-231 and (C) WiDr cell 
lines using compounds 3d-3f. The ECAR values were calculated using wave 
software. The average+SEM values of at least three independent experimental 
values were calculated. 
 
3.3 Conclusions 
In conclusion, we have synthesized chalcone based phenylcyanoacrylic acids 
as potential metabolic inhibitors. These inhibitors were evaluated for their cell 
proliferation inhibition and these compounds did not show any toxicity in 4T1, 
MCF7, MDA-MB-231, MIAPaCa2, and WiDr up to a concentration of 100 µM. 
However, since we envisioned to generate generally nontoxic compounds as 
metabolic inhibitors, we evaluated 3d-3f for their metabolic profile using seahorse 
XFe96 glycolytic and mitochondrial stress tests. These studies showed that 
compounds caused mitochondrial dysfunction in 4T1, MDA-MB-231, and WiDr 
cell lines. Glycolytic stress test showed that compounds had the greatest effect 
on MDA-MB-231 and WiDr. Further investigation of these compounds will involve 
determination of the mechanism for which oxidative phosphorylation and 
glycolysis are affected. A lead compound will be selected and evaluated for 






Synthesis of (E)-4-(3-(phenyl)-3-oxoprop-1-en-1-yl)benzaldehyde 3a 
Acetophenone (10 mmol) was dissolved in methanol (50 mL) and 5 mL 2.5M 
NaOH was added. 4-(dimethoxymethyl)benzaldehyde was added to the reaction 
mixture and stirred for ~30 min. TLC showed completion of the reaction and 
concentrated HCl (2 mL) was added. The reaction mixture was stirred for an 
additional 30 min at which point the reaction mixture was further diluted with water 
and subsequently filtered. Product was recrystallized in ethanol to afford the pure 
product (E)-4-(3-(phenyl)-3-oxoprop-1-en-1-yl)benzaldehyde 3a in ~75% yield. 
 
Synthesis of (E)-4-(3-(4-fluorophenyl)-3-oxoprop-1-en-1-yl)benzaldehyde 3b 
4′-Fluoroacetophenone (10 mmol) was dissolved in methanol (50 mL) and 5 mL 
2.5M NaOH was added. 4-(dimethoxymethyl)benzaldehyde was added to the 
reaction mixture and stirred for ~30 min. TLC showed completion of the reaction 
and concentrated HCl (2 mL) was added. The reaction mixture was stirred for an 
additional 30 min at which point the reaction mixture was further diluted with water 
and subsequently filtered. Product was recrystallized in ethanol to afford the pure 








3′,4′,5′-Trimethoxyacetophenone (10 mmol) was dissolved in methanol (50 mL) 
and 5 mL 2.5M NaOH was added. 4-(dimethoxymethyl)benzaldehyde was added 
to the reaction mixture and stirred for ~30 min. TLC showed completion of the 
reaction and concentrated HCl (2 mL) was added. The reaction mixture was 
stirred for an additional 30 min at which point the reaction mixture was further 
diluted with water and subsequently filtered. Product was recrystallized in ethanol 
to afford the pure product (E)-4-(3-oxo-3-(3,4,5-trimethoxyphenyl)prop-1-en-1-
yl)benzaldehyde 3c in ~80% yield. 
 
 
Synthesis of (E)-2-cyano-3-(4-((E)-3-(phenyl)-3-oxoprop-1-en-1-yl)phenyl)acrylic 
acid 3d 
(E)-4-(3-(4-fluorophenyl)-3-oxoprop-1-en-1-yl)benzaldehyde 3a (10 mmol)  was 
dissolved in acetonitrile (30 mL) followed by the addition of cyanoacetic acid 
(11mmol) and piperidine (11 mmol). The reaction mixture was then refluxed for 2 
hours, at which time TLC confirmed the completion of the reaction. The reaction 
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was then cooled to room temperature and dilute HCl was added. The resulting 
solid was then filtered and recrystallized to afford the pure product (E)-2-cyano-




1H NMR (500 MHz, DMSO-d6) δ 8.17 (d, J = 7 Hz, 2H), 8.08-8.00 (m, 6H), 7.73 
- 7.79 (m, 1H), 7.68 (t, J = 7 Hz, 1H), 7.58 (t, J = 8 Hz, 2H) 
13C NMR (126 MHz, DMSO-d6) δ 189.6, 163.3, 147.9, 143.2, 137.9, 137.5, 
135.3, 133.8, 130.4, 129.8, 129.3, 129.1, 124.1, 119.1,113.1 
 
Synthesis of (E)-2-cyano-3-(4-((E)-3-(4-fluorophenyl)-3-oxoprop-1-en-1-
yl)phenyl) acrylic acid 3e 
(E)-4-(3-(4-fluorophenyl)-3-oxoprop-1-en-1-yl)benzaldehyde 3b (10 mmol)  was 
dissolved in acetonitrile (30 mL) followed by the addition of cyanoacetic acid 
(11mmol) and piperidine (11 mmol). The reaction mixture was then refluxed for 2 
hours, at which time TLC confirmed the completion of the reaction. The reaction 
was then cooled to room temperature and dilute HCl was added. The resulting 
solid was then filtered and recrystallized to afford the pure product (E)-2-cyano-






1H NMR (500 MHz, DMSO-d6) δ 8.34 (s, 1H), 8.19 - 8.29 (m, 2H), 8.04 - 8.11 
(m, 4H), 7.74 (d, J = 16 Hz, 1H), 7.32 - 7.43 (m, 2H) 
13C NMR (126 MHz, DMSO-d6) δ 188.0, 166.6, 164.6, 163.6, 153.8, 142.8, 




yl)phenyl) acrylic acid 3f 
(E)-4-(3-(4-fluorophenyl)-3-oxoprop-1-en-1-yl)benzaldehyde 3c (10 mmol)  was 
dissolved in acetonitrile (30 mL) followed by the addition of cyanoacetic acid 
(11mmol) and piperidine (11 mmol). The reaction mixture was then refluxed for 2 
hours, at which time TLC confirmed the completion of the reaction. The reaction 
was then cooled to room temperature and dilute HCl was added. The resulting 
solid was then filtered and recrystallized to afford the pure product (E)-2-cyano-







1H NMR (500 MHz, DMSO-d6) δ 8.38 (s, 1H), 8.11 - 8.09 (m, 5H), 7.78 (d, J = 
20 Hz, 1H), 7.45 (s, 2H), 3.91 (s, 6H), 3.77 (s, 3H) 
13C NMR (126 MHz, DMSO-d6) δ 188.1, 163.6, 153.8, 153.4, 142.7, 142.6, 
139.4, 133.5, 133.2, 131.5, 130.0, 124.8, 116.6, 106.8, 104.8, 60.7, 56.7 
 
3.4b Cell lines and culture conditions 
4T1 cells were purchased from Caliper Life Sciences and were cultured in 
RPMI-1650 supplemented with FBS (10%) and penicillin-streptomycin (50 U/mL, 
50 µg/mL). 
MDA-MB-231 cells were purchased from ATCC and were cultured in 
DMEM supplemented with FBS (10%, Atlanta Biologicals) and penicillin-
streptomycin (50 U/mL, 50 µg/mL, Invitrogen).  
WiDr cells were purchased from ATCC and were cultured in MEM 
supplemented with FBS (10%) and penicillin-streptomycin (50 U/mL, 50 µg/mL).  
 
 
3.4c MTT assay 
Cells (5 x 103 cells/well) were cultured in 96-well plates and incubated for 
18-24 hours. Stock solution of compound was made up at 100 mM concentration 
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in DMSO. The final concentration of DMSO in the wells were < 0.01%. 
Concentration range of compounds from 50 µM to 0.5 µM was tested by adding 
2x concentration of test compound to the first well and then the serial dilutions by 
going from well to well. All the compounds were tested in duplicates. After 72 
hours of treatment, 10 µL of MTT (5 mM in 1x PBS) was added into the wells and 
the cells were incubated for a period of 4 hours. At this point, the conversion of 
MTT to formazan was quenched by the addition of 100 µL of SDS (1 g of SDS 
dissolved in 0.01 N HCl) and the cells were incubated for further 4 hours. The 
absorbance was recorded at 570 nm using BioTek Synergy 2 plate reader. The 
absorbance is directly proportional to the cell viability. % Survival was calculated 
using the formula  
 
3.4d Seahorse XFe96® assessment of glycolysis and mitochondrial 
respiration 
20,000 cells/well were plated in 96-well Seahorse plates (Agilent, part no. 
101085-004) and incubated 16-24 hours at 37⁰C at 5% CO2. Flux pack sensors 
(Agilent, part no. 102416-100) were hydrated with XF calibrant solution (Agilent, 
part no. 100840-000) overnight at 37⁰C in a non-CO2 incubator. Serum free assay 
media were prepared using Seahorse base medium (Agilent, part no. 102353-
100) with the addition of glutamine (1mM) and sodium pyruvate (1mM) for 
glycolysis stress test, whereas for mitochondrial stress test, glucose (10mM), 
glutamine (1uM), and sodium pyruvate (1mM) were used. The pH of these media 
was adjusted to 7.4 and warmed to 37oC. An 8X stock concentration of test 
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compounds was prepared for microplate injections in port A. Stock solutions of 
glucose, oligomycin, and 2-deoxyglucose (Chem Impex) were prepared such that 
their final working concentrations are 10mM, 1μM and 50mM, respectively, for 
glycolysis stress test. For mitochondrial stress test, stock solutions of oligomycin, 
FCCP, rotenone+antimycin A were prepared such that their final concentrations 
are 1 µM, 0.25-1 µM, and 0.5µM, respectively. Under glycolytic stress test, the 
cells were treated with test compounds, followed by the addition of glucose, 
oligomycin and 2-deoxyglucose at 14.29, 33.8, 53.35, 72.87 minutes, 
respectively. Under mitochondrial stress test, cells were treated with test 
compounds, followed by the addition of oligomycin, FCCP, and 
rotenone+antimycin A, at 14.29, 33.8, 53.35, 72.87 minutes, respectively. 
Extracellular acidification rates (ECAR) and oxygen consumption rates (OCR) 
were recorded in real-time for glycolysis and mitochondrial stress tests, 
respectively, using a Seahorse XFe96® analyzer (Agilent). The parameters 
related to glycolytic and mitochondrial functions were calculated utilizing the 
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